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ABSTRACT 
 
IMMUNOREGULATORY ACTIVITIES OF NANOPARTICLE-FORMING 
OLIGODEOXYNUCLEOTIDES 
Kutay Karatepe 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Dr. İhsan Gürsel 
August 2009, 99 pages 
 
 Innate immune system is activated by a wide range of microbial by products leading to 
an immediate immune activation primarily designed to neutralize and control the invading insult. 
The cells of the innate immune system also instruct the development of antigen-specific adaptive 
immunity. While TLR9 is triggered by bacterial DNA, extended and over-exuberant immune 
response poses a threat since it may exacerbate cell and tissue destruction leading to organ 
failure. Telomeric TTAGGG conserved motifs are previously reported to antagonize TLR 
mediated events. The down-regulatory effect of these motifs may help to restore the desired 
homeostatic balance of the immune system. While CpG ODN patterned after bacterial DNA can 
be harnessed in different clinical settings to provide an advantage to host to resist infectious 
diseases, control tumor growth or alleviate allergic symptoms, the immunosuppressive telomeric 
motifs could be effectively applied in controlling systemic anti-inflammatory or autoimmune 
related disorders. 
  Several challenges exist in the utilization of synthetic ODNs in the clinic. The first 
challenge is that conventional classes of synthetic ODNs exhibit different properties. K-type 
ODNs are more effective in proliferation and activation of B cells and DC. D-type ODNs are in 
nanoparticle forms, lead to anti-viral type I IFN production and mature monocytes into DCs. Of 
note, the efficacy of these synthetic ODNs is reduced under physiological conditions due to 
premature clearance and low levels of internalization. Moreover, D-ODNs as one of the most 
potent IFNα inducing TLR9 ligands possess a large-scale production problem due to 3’polyG-
runs, which hamper their entry into the clinic.   
We have designed a novel class of ODN, designated as ODN420, devoid of polyGs that 
can undergo nanoparticle formation necessary for its IFNα induction. Ex vivo stimulation of 
mouse splenocytes and in vivo administration of ODN420 have revealed that this ODN exhibits 
higher immunostimulatory potential and is more stable than most commonly used ODNs due to 
its nanoparticle-forming ability. Another interesting finding is that ODN420 with the natural 
phosphodiester (PO) backbone is at least as potent as its more stable counterpart with the 
modified phosphorothioate backbone. Furthermore, it combines superior properties of 
conventional classes of K and D-ODNs. These results have been reproduced in human peripheral 
blood mononuclear cells by various assays. 
Next, we have analyzed whether this ODN could be utilized as a vaccine adjuvant and an 
anti-cancer agent with two independent experiments. Our immunization results demonstrate that 
ODN420 induces a higher level of Th1-mediated response than conventional ODNs and is a 
promising candidate as a vaccine adjuvant. This response is hampered when ODN420 is used in 
combination with ODN-A151. In the tumor xenograft model, ODN420 has promoted partial 
remission of the tumors or delayed the tumor growth. This knowledge will pave the way for 
more effective immunotherapeutic approaches. 
 
Keywords: TLR, immunomodulatory DNA, nanoparticle, anti-cancer immunotherapy, vaccine
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ÖZET 
 
NANOPARÇACIK OLUŞTURAN OLİGODEOKSİNÜKLEOTİDLERİN 
İMMÜNMODÜLATÖR ETKİLERİ 
Kutay Karatepe 
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Danışman: Doç. Dr. İhsan Gürsel 
Ağustos 2009, 99 sayfa 
 
Doğal bağışıklık sistemi öncelikle değişik mikroorganizmaların yan ürünlerini tanıyarak 
mikroorganizmanın yayılmasını kontrol edecek mekanizmaları harekete geçirir. Bağışıklık 
sisteminin bu kolundaki hücreler aynı zamanda antijene özgü kazanılmış bağışıklık sistemi 
hücrelerini de uyarır.  
CpG-motifleri taşıyan bakteriyel DNA TLR9 almaçı tarafından tanınır. Ancak bağışıklık 
sisteminin uzun ve aşırı bir şekilde aktif halde olması organ hasarına kadar gidebilecek hücre ve 
doku yıkımına sebep olabilir. Memeli genomundaki korunmuş TTAGGG motiflerinin TLR 
almaçlarının sinyal yolaklarını bastırdığı daha önceden ispat edilmiştir. Bu baskılayıcı etki 
bağışıklık sisteminde homeostatik dengeyi tekrar eski haline getirir. Bakteriyel DNA’lardan 
esinlenmiş CpG-motifleri taşıyan sentetik DNA’lar bulaşıcı hastalıklar, kanser veya alerji gibi 
çeşitli klinik durumlarda kullanılabilirken, bağışıklık sistemini bastırıcı DNA parçacıkları 
antiinflamatuar etki gerektiren sistemik otoimmün hastalıklar için çözüm vaat etmektedir. 
Sentetik DNA parçacıklarının (ODN) klinikte kullanılmasının önünde çeşitli engeller 
bulunmaktadır. Şu ana kadar kullanılmakta olan ODN’ler ait oldukları alt sınıfa göre farklı 
etkilere yol açarlar. K-tipi ODN’ler B hücrelerinin ve dendritik hücrelerinin çoğalması ve 
aktivasyonunda daha etkilidir. D-tipi ODN’ler ise nanoparçacık yapısında olup anti-viral tip I 
interferon üretimini ve monositlerin dendritik hücrelere farklılaşmasını tetikler. Ayrıca bu 
sentetik ODN’lerin hücre içine alınmadan nükleazlar tarafından parçalanması bunların fizyolojik 
koşullardaki etkinliğini azatmaktadır. Son olarak, interferon-alfa üretimini tetikleyen D-tipi 
ODN’ler poli-G uçları içerdiğinden farkı büyüklükte parçacıklar oluşturur. Heterojen yapılar 
oluşturan D-tipi ODN’lerin büyük ölçekli üretimi ve klinikte kullanımı problemlidir. 
Biz poli-G ucu içermeyen, interferon-alfa üretimini tetikleyebilecek homojen 
nanoparçacıklar oluşturan ODN420 adını verdiğimiz yeni bir sınıf ODN geliştirdik. Fare dalak 
hücrelerinin ex vivo uyarımı ve bu ODN’lerin in vivo enjeksiyonu sonucunda elde ettiğimiz 
sonuçlar ODN420’nin daha önceden kullanılan ODN’lere göre bağışıklık sistemini daha yüksek 
seviyede tetiklediğini ve nanoparçacık yapısından ötürü eksonükleazlara göre daha dirençli 
olduğunu gösterdi. Aynı zamanda bu ODN’nin doğal fosfodiester iskelet içeren halinin daha 
stabil olan modifiye edilmiş fosforotioat iskeletli haliyle benzer aktivite gösterdiğini bulduk. 
Ayrıca, bu ODN’nin K ve D-tipi ODN’lerin üstün özelliklerini taşıdığını gösterdik. Bu sonuçlar 
insan kanından izole edilmiş bağışıklık sistemi hücrelerinde de tekrar gösterildi. 
Sonra iki farklı hayvan deneyinde bu ODN’nin aşı adjuvanı ve anti-kanser ajanı olarak 
potansiyelini inceledik. Aşı deneyindeki sonuçlar ODN420’nin şu anda kullanılan ODN’lere 
göre daha etkin bir antijene özgü Th1 etkisi yarattığını ve bu etkinin ODN-A151 tarafından 
azaltıldığını bulduk. Tümör modelinde ise ODN420, tümörün büyümesini tersine çevirdi veya 
geciktirdi. Bu bulgular bağışıklık sisteminin manipülasyonuyla daha etkin tedavi yöntemleri 
bulunmasına ışık tutacaktır. 
Anahtar kelimeler: TLR, immunomodülatör DNA, nanoparçacık, anti-kanser terapi, aşı 
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 1. INTRODUCTION 
1.1.  Immune System 
All vertebrates constantly encounter potentially harmful foreign substances, 
known as “antigens”. In order to protect the body from foreign antigens by distinguishing 
them from the organism’s normal cells and tissues, the cells of the immune system are in 
a state of constant surveillance.  
The first line of defense is formed from the physical barriers provided by our skin 
and mucosa. If this primary defense of line cannot prevent pathogens from entering the 
organism, the innate immune system is activated by the “danger signal”. According to the 
“danger signal” principle, cells of the innate arm of the immune system detect a specific 
signature molecule commonly expressed on a large verity of pathogens. These molecules, 
also known as Pathogen Associated Molecular Patters (PAMP) are absent on the host’s 
own cells and are recognized by germline encoded Pattern Recognition Receptors (PRR) 
of the cells of innate immunity. Upon an encounter with the “danger signal”, these cells 
mount a robust increase in the production of inflammatory molecules so that the invading 
infectious organism can be contained and eradicated. In most cases, encounters between 
antigens and immune cells pass by unnoticed, due to the effective protective mechanisms 
provided by these primary lines of defense. 
 In certain cases, these lines of defense are breached and the innate immune system 
cannot contain the infection. This results in the activation of the adaptive immune system 
and the cooperation between the innate immune system and adaptive immune system 
allows the clearance of the pathogen. This thesis focuses on manipulation of the innate 
immune system for therapeutic purposes and thus, the details regarding the function of 
the adaptive immune system are beyond the scope of this study. Therefore, briefly, 
adaptive immunity is mainly characterized by clonally expanded T cells and B cells. 
These cells make use of highly specific antigen receptors -T cell receptor (TCR) and B 
cell receptor (BCR), respectively- to individual antigenic peptide molecules. 
Furthermore, unlike the cells of the innate immune system, they are able to retain 
memory for a previously encountered antigen.
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 Antigen presenting cells (APCs), including dendritic cells (DCs), macrophages 
and B cells, are found in their immature state throughout the body at the possible entry 
sites of pathogens such as mucosal surfaces and skin. Upon recognition of pathogens, 
DCs phagocytose and process the microbial antigens to their peptide content. These 
antigens are loaded onto major histocompatibility complex (MHC) class I and II 
molecules for presentation to CD8+ and CD4+ T cells, respectively. During this 
maturation process, DCs upregulate the chemokine receptor CCR7 and migrate towards 
the draining lymph node, the site of antigen presentation. Additionally, the expression of 
co-stimulatory molecules (i.e. CD80 and CD86) and cytokines required for effective 
activation of T cells is up-regulated and MHC molecules are translocated from the 
intracellular vesicles to plasma membrane. In the lymph node, upon proper antigen 
recognition, naïve lymphocytes become activated (Janeway, 2001; Lee and Iwasaki, 
2007). When the strong and specific response generated by the adaptive immune system 
is dysregulated, however, it becomes responsible for allergy and autoimmunity. Adaptive 
immunity is also responsible for tissue rejection cases in transplantation surgeries. The 
major differences between innate immune system and adaptive immune system are given 
in Table 1. 
 
Table 1. The cardinal features of innate and adaptive immunity.  (Janeway and 
Medzhitov, 2002) 
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 1.2. Innate Immune System 
The innate immune system recognizes and responds to pathogens in a non-
specific manner. Due to the generic mechanisms activated by innate immune system, it 
does not accommodate long-lasting or protective immunity to the host (Alberts, 2008). 
The major functions of the vertebrate innate immune system include: 
• Recruitment of immune cells to sites of infection and inflammation through the 
production of cytokines, 
• Activation of the complement cascade to identify bacteria, activate cells and to 
promote clearance of dead cells or antibody complexes, 
• Identification and removal of foreign substances present in organs, tissues, blood 
and lymph by specialized white blood cells, 
• Activation of the adaptive immune system through a process known as antigen 
presentation. (Murphy et al., 2008) 
Major cell types in the innate immune system are natural killer (NK) cells, mast 
cells, eosinophils, basophils and phagocytes (i.e. neutrophils, monocytes/macrophages, 
DCs). NK cells destroy infected cells in a process known as “missing self”. As MHC I 
molecule, located on the surface of all hosts cells, tags the cells as “self”, the 
downregulation or absence of this molecule activates NK cells for killing. Such is the 
case of virally infected hosts cells that down regulate cell-surface MHC I molecules 
(Murphy et al., 2008). NK cells also attack tumor cells by various mechanisms (Raulet 
and Guerra, 2009). 
Mast cells release characteristic granules rich in histamine and heparin, along with 
various hormonal mediators and chemokines. Histamine promotes dilation of blood 
vessels, a characteristic sign of inflammation, and recruits other immune cells to sites of 
infection. Although mast cells are primarily responsible for wound healing and defense 
against pathogens, they are also associated with allergy and anaphylaxis. (Murphy et al., 
2008) 
Basophils and eosinophils are known as granulocytes along with neutrophils due 
to the presence of granules in their cytoplasm. Basophils release histamine and 
eosinophils release a variety of toxic proteins. These products are effective in killing 
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 pathogens. They are, however, also responsible for tissue damage during allergic 
reactions such as asthma (Macfarlane et al., 2000). 
Phagocytes of the innate immune system include neutrophils, macrophages and 
DCs. Neutrophils are the most abundant type of phagocytes and comprise approximately 
50-60% of total circulating leukocytes. Neutrophils are usually the first cells to arrive at 
the site of an infection. Their granules contain toxic substances that kill or inhibit growth 
of bacteria and fungi. Upon binding of bacterial molecules to receptors on neutrophils, 
neutrophils activate a “respiratory burst” causing the generation of reactive oxygen 
species such as hydrogen peroxide (H2O2). Macrophages are another type of cell that 
utilizes a similar “respiratory burst”. They are the most efficient phagocytes and can 
phagocytose a substantial number of pathogens. The precursors of these tissue-resident 
macrophages are blood circulating monocytes. As mentioned previously, DCs are the 
major cell type responsible for antigen presentation. Hematopoietic bone marrow 
progenitor cells transform into immature dendritic cells characterized by high endocytic 
activity and low T-cell activation potential. Immature DCs circulate throughout the body 
and upon pathogen recognition, they phagocytose pathogens, process antigenic molecules 
into peptides and present them to T cells, thereby activating adaptive immune system 
(Banchereau and Steinman, 1998). In addition to their antigen presentation function, 
macrophages and DCs also induce a number of cytokines and chemokines, which allow 
recruitment of other immune cells to sites of infection, during the onset of innate immune 
activation. The properties of major cytokines and chemokines are given in Table 2 and 
Table 3. 
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 Table 2. Cytokines affect behavior of target cells. (Janeway, 2005; Murphy et al., 2008) 
Mf: Macrophages, T: T cells, DC: Dendritic cells, NK: Natural Killer cells 
Cytokines  Produced by  Function 
IL‐1β  Mf, keratinocytes  Fever, induction of acute‐phase protein secretion,  
T cell and Mf activation 
TNFα  Mf, DC, NK and  
T cells 
Local inflammation and endothelial activation 
IL6  Mf, DC  Fever, T and B cell growth and differentiation 
IL‐12  Mf, DC  Activation of NK cells, induction of CD4 T‐cells to 
differentiate into TH1 
IL‐15  Many non‐T cells  CD8 memory T cell survival, stimulation of NK and T cell 
growth 
IL‐18  Activated Mf  Induction of IFNγ secretion via NK and T cells, favors TH1 
immunity 
IFNα  DC  Anti‐viral immunity, induction of MHC I expression 
IFNγ  T cells, NK cells  Suppression of TH2 immunity, Mf activation, increased 
expression of antigen processing components 
 
Table 3. Chemokines recruit target cells to sites of infection. (Janeway, 2005; Murphy et 
al., 2008) 
Chemokines Produced by Attracted cells Major effect 
CXCL8 
(IL‐8) 
Monocytes, Mf, DC  Neutrophils, 
naïve T cells 
Mobilization, activation and 
degranulation of neutrophils 
CCL3  
(MIP‐1α) 
Monocytes, T, Mast cells, 
fibroblasts 
Monocyte,NK, T, 
basophil, DC 
Promotes TH1, 
antiviral defense, 
competes with HIV‐1 
CCL4 
(MIP‐1β)  
Monocytes, Mf, Neutrophils, 
endothelium 
Monocyte, NK, T, 
DC 
Competes with HIV‐1 
CCL2 (MCP‐1)  Monocyte, Mf, fibroblast, 
keratinocyte 
Monocyte, NK, T, 
basophil, DC 
Promotes TH2, activate Mf, 
histamine release from basophils 
CXCL10 (IP10)  T, fibroblast, endothelial, 
monocyte, keratinocyte 
Resting T cells, 
NK, monocytes 
Promotes TH1, antiangiogenic, 
immunostimulant 
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 1.2.1. Pathogen Recognition Receptors (PRR) 
 While T cell and B cell receptors are formed by rearrangements in gene segments 
and can recognize an infinite variety of antigens, the receptors of innate immune system 
are germline-encoded pattern recognition receptors (PRR). These receptors recognize 
certain signature patterns on pathogens termed as pathogen-associated molecular patterns 
(PAMP). These include viral nucleic acids, components of bacterial and fungal cell walls 
and many more. For a long time, innate immunity has been considered as a non-specific 
immune response characterized by engulfment and digestion of microorganisms and 
foreign substances by phagocytic cells (Akira et al., 2001). The discovery of PRRs, the 
specificity of response generated by these cells and the notion that their ligands, PAMPs, 
can be utilized as adjuvants has fueled interest in the previously underestimated field of 
innate immunity. 
 PRRs share common properties among themselves. First, PAMPs recognized by 
PRRs are essential for the survival of the microorangism and are therefore difficult for 
the microorganism to modify. Second, PRRs are expressed constitutively in the host and 
detect the pathogens regardless of their life-cycle stage. Third, PRRs are germline 
encoded, nonclonal and expressed on all members of a given cell type. Furthermore, cells 
carrying these receptors lack immunologic memory. Finally, the basic components of 
innate immunity are highly conserved among species, from plants and fruit flies to 
mammals (Akira et al., 2006). 
 There are different PRR families and these are outlined in Table 4. Mannan-
binding lectin (MBL), C-reactive protein (CRP), and serum amyloid protein (SAP) are 
secreted PRRs produced by the liver during the acute phase response at the early stages 
of infection. While CRP and SAP are members of the pentraxin family, MBL is a 
member of the collectin family. CRP and SAP bind to phosphorylcholine on bacterial 
surfaces and opsonize microorganisms leading to their phagocytosis. MBL binds 
specifically to terminal mannose residues, which are abundant on the surface of many 
microorganisms, it initate the lectin pathway of complement by cleaving C2 and C4 
proteins.  
 In addition to these extracellular PRRs, many PRRs reside on the plasma 
membrane. One family of PRRs, which is located on the plasma membrane, is scavenger 
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 receptors. Macrophage scavenger receptor (MSR) has a broad specificity to a variety of 
ligands, such as double-stranded RNA (dsRNA), LPS, and LTA. Another scavenger 
receptor expressed on macrophages is MARCO, which binds to bacterial cell walls and 
LPS, and also mediates phagocytosis of bacterial pathogens (Janeway and Medzhitov, 
2002). 
 NOD-like receptors (NLRs) and RIG-like helicases (RIHs) are two major families 
of PRRs found in the cytoplasm. NOD1 and NOD2 detect bacterial peptidoglycan, drive 
activation of mitogen-activated protein kinases (MAPKs) and NF-kB. The minimal 
structural requirement for activation of NOD2 is muramyl dipeptide, a structure present 
in both Gram-positive and Gram-negative bacteria. NALP proteins such as NALP1, 
NALP2 and NALP3 also belong to NLR family of PRRs. They have a cruicial role in 
activation of proinflammatory caspases through formation of a complex called the 
inflammasome. Retinoic-acid-inducible gene I (RIG-I) and melanoma-differentiation-
associated gene 5 (MDA5) are two members of RIH family. They are activated by 
dsRNA during a viral infection and trigger the activation of NF-kB and IRF3/7, which 
cooperate in induction of antiviral type I IFNs (Meylan et al., 2006). 
 
Table 4. PRR families in mammalian cells and their associated ligands.  (Lee and Kim, 
2007) 
 
7 
 
  
1.2.1.1.  Toll-like Receptors (TLRs) 
The main focus in this study is toll-like receptors (TLR), which are the most 
extensively studied and characterized family of PRRs. Mammalian TLRs are homologous 
to the Drosophila Toll receptor (Medzhitov et al., 1997). These evolutionarily conserved 
receptors belong to the IL-1R superfamily, characterized by an extracellular leucine-rich 
repeats (LRR) and an intracellular Toll/IL-1 receptor like (TIR) domain (Medzhitov, 
2001). Members of TLR family differ from each other in their ligand specificities, 
expression patterns, and the downstream signaling pathways.  
TLRs in the innate immune system serve an essential role not only in recognition 
of pathogen, but also in directing the course and type of innate immune response 
generated following an exposure to foreign antigen (Takeda et al., 2003). TLRs have 
been demonstrated to have a wide array of functions including initiation of 
proinflammatory responses and antiviral responses, up-regulation of costimulatory 
molecules on antigen presenting cells (APC), release of chemokines to induce migration 
of responder cells to the site of infection and cross-priming of T cells by DCs (Takeda 
and Akira, 2005). TLRs are responsible for the adjuvant activity that is required to initiate 
immune responses both in natural infection and in vaccine responses (Lien and 
Golenbock, 2003). TLRs also have an essential role in shaping adaptive immune 
responses to pathogen. The signals for activation of adaptive immunity are mostly 
provided by DCs. TLR-mediated recognition of pathogens by DCs induces the expression 
of costimulatory molecules such as CD80/CD86 required for the effective activation of T 
cells and production of inflammatory cytokines such as IL-12 (Akira et al., 2001). DC 
subsets can induce cellular immunity (Th1) and humoral immunity (Th2). Activation of 
TLR9 in DCs induces production of IL-12, thereby changing the helper T cell (Th) 
differentiation toward Th1 type. LPS stimulates TLR4 signaling pathway and allows DCs 
to support both Th1 and Th2 cell differentiation (Kaisho et al., 2002). Additionally, some 
pathogen-derived adjuvants such as Complete Freund’s Adjuvant (CFA), Bacille 
Calmette Guerin of Mycobacterium bovis (BCG) are recognized by TLRs; TLR9 and 
TLR2, TLR4 respectively, which may explain the involvement of TLRs in adaptive 
immunity (Akira et al., 2003).  
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 Human TLR4 is the first characterized mammalian Toll-like receptor. It is 
expressed in a variety of cell types, most predominantly in the cells of the immune 
system, including macrophages and DCs (Medzhitov et al., 1997). TLRs can be classified 
according to their localization in the cells. While TLR1, 2, 4, 5, 6 and 10 are localized on 
the plasma membrane and recognize mainly extracellular bacterial products, TLR3, 7, 8 
and 9 are located in the intracellular endosomal and/or ER compartments and recognize 
viral or bacterial nucleic acids (Iwasaki and Medzhitov, 2004; Latz et al., 2004). 
Subcellular localizations and ligands of TLRs are given in detail in Figure 1. 
 
 
Figure 1. TLR family members and their subcellular localizations (Takeda and Akira, 
2005). 
 
1.2.1.1.1. TLR 1, TLR2 and TLR6 
TLR2 responds to various microbial products, including lipoproteins, Gram-
positive bacterial PGN and LTA, lipoarabinomannan from mycobacteria, 
glycosylphosphatidylinositol anchors from a protozoan Trypanosoma cruzi, a phenol-
soluble modulin from Staphylococcus epidermis, zymosan from fungi (Takeda and Akira, 
2005). The wide spectrum recognition of microbial components by TLR2 is due to its 
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 ability to form heterodimers with other TLRs such as TLR1 and TLR6. Inflammatory 
response to mycoplasma-derived triacyl and diacyl lipopeptides is deficient in TLR6 and 
TLR1 deficient mice, respectively. This proves that TLR1 and TLR6 functionally 
associate with TLR2 to discriminate between diacyl or triacyl lipopeptides. TLR2 has 
also shown to functionally collaborate with other distinct types of receptors such as 
dectin-1, a lectin family receptor for the fungal cell wall component β-glucan (Sato et al., 
2000). 
 
1.2.1.1.2.  TLR3 
TLR3 is located in endosomal compartments. It recognizes double-stranded RNA, 
which is produced by most viruses during their replication. This discovery led to the 
notion that TLRs may have a key role in the host defense against viruses by enhancing 
NF-kB and interferon (IFN)-regulatory factor 3 (IRF3) pathways (Alexopoulou et al., 
2001). Upon dsRNA recognition, type I interferons (IFNα/β), which exert anti-viral and 
immunostimulatory activities, are induced. NK cells are the major players in anti-viral 
immunity and express TLR3. They are activated directly in response to synthetic dsRNA, 
polyriboinosinic polyribocytidylic acid (poly I:C) (Schmidt et al., 2004). Also, myeloid 
DCs produce IL-12 and IFN-β upon TLR3 activation (Ito et al., 2002b).  
 
1.2.1.1.3.  TLR4 
As mentioned above TLR4 is the first identified mammalian Toll. This 
extracellular TLR is expressed in variety of cell types, most predominantly in 
macrophages and DCs (Medzhitov et al., 1997). The major ligand of TLR4 is 
lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative 
bacteria (Hoshino et al., 1999). Recognition of LPS by TLR4 is complex and requires 
several accessory molecules. LPS is first bound to a serum protein, LPS-binding protein 
(LBP), which functions by transferring LPS monomers to CD14 (Wright et al., 1989). 
Another component of the LPS receptor complex is MD-2 (Shimazu et al., 1999). 
Although its precise function is not known, MD-2 is also required for LPS recognition 
(Schromm et al., 2001). 
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1.2.1.1.4.  TLR5 
TLR5 recognizes flagellin, the protein subunits that make up bacterial flagella. 
TLR5 is expressed on the basolateral side of the intestinal epithelium, where it can sense 
flagellin from pathogenic bacteria, such as Salmonella. Flagellin induces lung epithelial 
cells to induce inflammatory cytokine production (Hawn et al., 2003). 
 
1.2.1.1.5.  TLR7 and TLR8 
Both TLR 7 and 8 are structurally highly conserved proteins. Although both of 
these TLRs are expressed in mice, mouse TLR8 appears to be nonfunctional (Akira et al., 
2006). It has been revealed that murine and human TLR7, but not murine TLR8,  
recognizes synthetic compounds, imidazoquinolines (R848), which are clinically used for 
treatment of genital warts associated with viral infection (Hemmi et al., 2002). Murine 
TLR7 and human TLR8 recognize guanosine or uridine-rich single-stranded RNA 
(ssRNA) from viruses such as HIV, vesicular stomatitis virus and influenza virus. ssRNA 
is abundant in host but the endosomal localization of TLR7 and TLR8 prevent access of 
these receptors to self ssRNA (Lund et al., 2004). 
 
1.2.1.1.6.  TLR9 
One of the most known TLRs, TLR9 is the receptor for bacterial genomic DNA, 
which is rich in unmethylated CpG motifs. TLR9 is primarily expressed in B cells, DCs 
and macrophages although its expression pattern differs between mice and humans. 
Human cells have a more restricted expression of TLR9 (Table 5). A single nucleotide 
substitution or methylation of a cytosine residue within the CpG motif completely 
abrogates the immunostimulatory property of bacterial DNA (Krieg et al., 1995). There 
are different types of synthetic CpG-DNA and their therapeutic potentials are discussed 
in detail in subsequent sections. 
In addition to recognition of bacterial and viral CpG DNA, TLR9 is presumably 
involved in pathogenesis of autoimmune disorders. The immunoglobulin-G2a (IgG2a) is 
bound and internalized by the B cell receptor, and the chromatin, including 
hypomethylated CpG motifs, is then able to engage TLR9, thereby inducing rheumatoid 
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 factor. Chloroquine, a chemical which blocks TLR9 dependent signaling, is widely used 
for treatment of autoimmune diseases such rheumatoid arthritis and systemic lupus 
erythematosus (SLE) (Boule et al., 2004). Proposed role of TLR9 in SLE is illustrated in 
Figure 2. 
 
Table 5. TLR9 expression varies among mice and human (Krieg, 2006). 
  B-cells pDC mDC monocyte/Mf
Human yes yes no no 
Mouse yes yes yes yes 
pDC: plasmacytoid DC; mDC: myeloid DC; Mf: macrophage 
 
1.2.1.2. TLR Signaling Pathways 
Activation of TLRs by PAMPs leads to induction of various genes involved in 
host defense. These induced genes include inflammatory cytokines, chemokines, MHC 
molecules and co-stimulatory molecules. Mammalian TLRs also induce multiple effector 
molecules such as inducible nitric oxide synthase (iNOS) and antimicrobial peptides, 
which can directly eliminate microbial pathogens. Although both TLRs and IL-1Rs rely 
on TIR domains to activate NF-κB and MAP kinases and share some target genes, a 
growing body of evidence points to several differences in signaling pathways activated 
by individual TLRs. All TLR family members use a common MyD88 adaptor, except for 
TLR3, which recruits TRIF. TLR4 is the only family member that activates both 
MYD88-dependent and TRIF-dependent signal transduction pathways (Barton and 
Kagan, 2009). 
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Figure 2. Self-DNA containing immune complexes is recognized by TLR9 and lead to 
the autoimmune disorder, SLE. (Rahman and Eisenberg, 2006) 
. 
Furthermore, activation of specific TLRs leads to slightly different patterns of 
gene expression profiles. While activation of TLR3 and TLR4 signaling pathways results 
in induction of type I IFNs (Doyle et al., 2002), TLR2- and TLR5-mediated pathways do 
not induce these anti-viral IFNs (Hoshino et al., 2002).  TLR7, TLR8 and TLR9 signaling 
pathways also lead to induction of type I IFNs in a different manner (Ito et al., 2002a).  
1.2.1.2.1.  MyD88-Dependent Pathway 
MyD88, comprised of a C-terminal TIR domain and an N-terminal death domain, 
associates with the TIR domain of TLRs. After stimulation, MyD88 recruits IL-1 
receptor-associated kinase-4 (IRAK-4) to TLRs through the interaction of the death 
domains of both molecules. Following this, it facilitates IRAK-4-mediated 
phosphorylation of IRAK-1. Activated IRAK-1 then associates with TRAF6, leading to 
the activation of two distinct signaling pathways. One pathway leads to activation of AP-
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 1 transcription factors through activation of MAP kinases. Another pathway activates the 
TAK1/TAB complex, which enhances activity of the Inhibitor kappa B kinase (IkK) 
complex. Once activated, the IkK complex induces phosphorylation and subsequent 
degradation of IkB, which leads to nuclear translocation of transcription factor NF-kB 
(Klinman, 2004; Takeda and Akira, 2004). MyD88-deficient mice do not show 
production of inflammatory cytokines such as TNF-α and IL-12p40 in response to any 
TLR ligand (Takeuchi et al., 2000). This once again proves that MyD88 is essential for 
inflammatory cytokine production through all TLRs. MyD88-deficient macrophages, 
show impaired inflammatory cytokine production in response to TLR4 and TLR2 ligands 
in contrast to TLR3, TLR5, TLR7 and TLR9 ligands (Yamamoto et al., 2002a). 
1.2.1.2.2.  MyD88-Independent/TRIF-Dependent Pathway 
While TLR4 ligand-induced production of inflammatory cytokines is not 
observed in MyD88-knock-out macrophages, delayed NF-κB expression is observed. 
This shows that although TLR4 signaling relies on MyD88-dependent pathways, a 
MyD88-independent component exists in TLR4 signaling. TLR4-induced activation of 
IRF-3 leads to production of IFN-β, which in turn activates Stat1 and induces several 
IFN-inducible genes, like TLR3 (Alexopoulou et al., 2001; Yoneyama et al., 1998). 
TRIF-deficient mice exhibit impaired expression of IFN-β and IFN-inducible genes in 
response to TLR3 and TLR4 ligands (Yamamoto et al., 2002b). Studies with other TRIF-
related adaptor molecules TRAM/TICAM-2 showed that TRAM is involved in TLR4-
mediated, but not TLR3-mediated, activation of IRF-3 and induction of IFN-β and IFN-
inducible genes (Yamamoto et al., 2003). Key molecules that mediate IRF-3 activation 
have been revealed to be non-canonical IkKs, Tank binding kinase-1 (TBK1) and 
IkKi/IkKe (Fitzgerald et al., 2003). It has been recently reported that complete MyD88 
and TRIF expression is required for the effective cooperation, resulting in the induction 
of IL-12, IL6, and IL-23 but not of TNF-α and IP-10 upon MyD88- and TRIF-dependent 
TLR stimulation. Downstream of MyD88, TRIF and IRF5 are identified as essential 
transcription factors for the synergism of IL6, IL-12, and IL-23 gene expression (Ouyang 
et al., 2007). TRAF6 associates with the N terminal portion of TRIF and the C-terminal 
portion of TRIF associates with receptor-interacting protein-1 (RIP1), thereby leading to 
NF-kB activation (Gohda et al., 2004; Meylan et al., 2004).  
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 1.3.  A Deeper Insight into Immunostimulatory DNA Particles and TLR9 
Activation 
TLR9 is the only known member of TLR family that can recognize specific DNA 
motifs. Five years after the identification of CpG motifs, Hemmi et. al. reported that 
TLR9 is responsible for the recognition of CpG DNA in mice. They showed that 
splenocytes, lymph node cells, dendritic cells, and macrophages from TLR9-deficient 
mice do not respond to CpG motif expressing oligodeoxynucleotides (CpG ODN), 
evident from the loss of pro-inflammatory cytokine production or cell surface maturation 
marker downregulation. Moreover, these mice are resistant to harmful side effects of 
CpG ODN (Hemmi et al., 2000). It has later been shown that human TLR9 is also 
prerequisite for bacterial DNA/CpG DNA-dependent immunostimulation in both primary 
cells and TLR9-transfected cell lines (Bauer et al., 2001; Takeshita et al., 2001). Later 
findings challenged the idea that recognition of foreign DNA is restricted to CpG motifs. 
Non-CpG phosphodiester ODNs (PO-ODNs), which are delivered into endosomes via 
DOTAP complexation, and self chromatin DNA/IgG autoantibody complexes have been 
shown to be recognized via TLR9 (Boule et al., 2004; Yasuda et al., 2006). Recently, 
TLR9 has been shown to recognize 2’-deoxyribose sugar backbone (base-free) of 
phophodiester DNA -but not phosphorothioate (PS) modified 2’-deoxyribose, PS or PO 
modified 2’-ribose backbones- and activate cytokine secretion. Immunostimulatory 
activity and TLR9 affinity is increased further, when bases and CpG motifs are added to 
this backbone. PolyG addition (24 extra guanosines at 3’end) or DOTAP complexations 
are used here to target sugar backbone or PO-ODN into endosomes. PS-modified sugar 
backbones exhibit higher affinity to TLR9 and TLR7 than PO-modified counterparts both 
in vitro and in vivo (Haas et al., 2008). 
In unstimulated cells, TLR9 is localized to endoplasmic reticulum, which is 
transported to early endosomes and then lysosomes upon CpG stimulation (Latz et al., 
2004). It has been suggested that the transfer from ER to endosomes is mediated by 
UNC93B1 protein (Kim et al., 2008). Two independent studies reveal that the ER to 
endosome docking is mediated by endosomal localization motifs present on TLR9 which 
are on opposite locations on ER and endosomes (Barton et al., 2006; Leifer et al., 2006). 
There exist other controversial data on TLR9 translocation from ER to endosomes. Latz 
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 et al. reported that this translocation is mediated by non-secretory pathway (Latz et al., 
2004), while Chockalingam et al. reported that secretory pathway is involved and TLR9 
passes through Golgi on the way to endosomes (Chockalingam et al., 2009). In 
endosomes, TLR9 exists as homodimers and the ligand unbound form represents the 
inactive conformation of the receptor. Upon ligand binding, seperate TIR domains gets 
closer and recruit MyD88 for initiation of signaling cascade (Latz et al., 2007). Fitting 
with this idea, it has been shown that only aggregated, multimeric forms of ODNs are 
stimulatory. As concentration of multimeric forms increases in ODN solution, the 
immunostimulatory activity is enhanced (Wu et al., 2004). 
Interaction of TLR9 with bacterial/viral DNA in endosomes of wild-type cells 
seems to prevent recognition of self-DNA. Expression of TLR9 on the plasma membrane 
by generating a chimeric protein (TLR9/TLR4) makes mammalian DNA stimulatory. 
Viral DNA becomes inactive in this case possibly due to the coat around the DNA. 
Mammalian DNA with phosphodiester backbone exhibits parallelism with PO-ODNs, 
which become more stimulatory against surface expressed TLR9, in sensitivity to DNase 
(Barton et al., 2006). This finding challenges previous notion that CpG motifs are critical 
factors in of self/non-self discrimination. Recently, TLR9 has been shown to become 
activated after proteolytic cleavage of carboxy terminal fragment at endosomes via 
cathepsin proteases (Ewald et al., 2008; Park et al., 2008). This explains the previous 
observation that TLR9 signaling is blocked by inhibition of endosomal acidification 
(Ahmad-Nejad et al., 2002). This acidification is required for optimal activity of TLR9-
cleaving proteases. These recent findings strengthen the hypothesis that self/non-self 
discrimination is mainly achieved by TLR9 compartmentalization as it is functional in 
endosomes. 
  
1.3.1.  Accessory Molecules Involved in TLR9 Activation  
LL37: LL37 is an endogenous antimicrobial peptide expressed highly in psoriatic skin. 
During physical injury, disease condition worsens, self-DNA is released and pDC 
activation occurs. LL37 forms complexes with self-DNA. These complexes are delivered 
to early endosomes in pDC and IFNα is induced. Otherwise, self-DNA is inactive since it 
cannot colocalize with TLR9 in endosomes (Lande et al., 2007).  
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 HMBG1 and RAGE: HMBG1 (High-mobility group box 1) is another DNA-binding 
protein. It is involved in bending of double-helix to increase affinity of DNA to 
transcription factors. HMGB1 interacts and preassociates with TLR9 in the endoplasmic 
reticulum-Golgi intermediate compartment (ERGIC), and hastens TLR9’s redistribution 
to early endosomes in response to CpG DNA (Ivanov et al., 2007). Recent work shows 
that HMBG1 forms complexes with A/D-type ODN (but not B/K-type ODN), thereby 
increasing B cell activating and IFNα-inducing potential of pDC. This stimulation also 
depends on the interaction of RAGE (receptor for advanced glycation end-products), a 
multi-ligand receptor of immunoglobulin superfamily, with HMBG1-TLR9 complex. The 
critical roles of HMBG1 and RAGE in IFNα induction by DNA-containing immune 
complexes have also been shown in lupus patients (Tian et al., 2007). 
 
Cathepsin-K: Cathepsin-K is an osteoclast-specific protease which is involved in 
degradation of bone matrices. It is seen as a therapeutic target to treat diseases, such as 
osteoporosis and autoimmune arthritis, in which osteoclast activity abnormally increases. 
Recently, specific inhibition of Cathepsin-K by pharmacological inhibitor in dendritic 
cells, has been shown to reduce TLR9-mediated, but not TLR2 or TLR4-mediated, 
production of IL-12, IL-23 and upregulation of maturation markers such as CD40, CD80 
and CD86 in a dose-dependent manner. Moreover, cathepsin K-/- mice are found to be not 
responsive to stimulation with CpG ODNs (Asagiri et al., 2008). 
 
UNC93B1: Missense mutation in Unc93b1 gene is called 3d mutation because of the 
impaired signalling via TLR3, 7 and 9. Mice with 3d mutation show increased 
susceptibility to murine cytomegalovirus (MCMV) infection (Tabeta et al., 2006). 
UNC93B1 functions in delivery of TLRs from endoplasmic reticulum to endosomes. 
Mice with artificially expressed TLR9 on plasma membrane are not affected from 3d 
mutation and can respond to CpG motifs (Kim et al., 2008). 
 
1.3.2.  Different Classes of Synthetic CpG-ODNs  
Oligodeoxynucleotide (ODN) sequences designed for antisense therapy have first 
been shown to be immunostimulatory in 1992 (Yamamoto et al., 1992). Some antisense 
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 ODNs containing palindromic sequences have induced strong type I and/or type II IFN 
production and led to profound interferon mediated NK cell killing activity. Later, this 
activation has been attributed to the presence of unmethylated CpG motifs, which are 
nearly 20 times more frequently expressed in microbial DNA than mammalian DNA 
(Krieg et al., 1995). CpG motif expressing ODNs stimulate murine B-cell proliferation 
and IgM production significantly. Meanwhile, control ODNs in which cytosines are 
methylated or CpG is inverted to GpC does not exhibit any stimulatory effects. Minimum 
ODN length for stimulatory effect has been shown 8 bp. CpG ODNs stimulate BALB/c 
mice spleen cells to produce IL6, IL-12 and IFNγ. If a sequence contains multiple CpG 
motifs over a single strand, the stimulatory activity is enhanced (Klinman et al., 1996). 
CpG ODN also stimulates human PBMC to release TNFα, IL12, IL6 and upregulate 
monocyte and B-cell activation markers (Bauer et al., 1999). They induce polyclonal 
activation and differentiation of memory B cells into plasma cells without B-cell receptor 
signaling or T cell help. This makes CpG ODNs candidates as powerful adjuvant for 
induction of humoral immunity. However, BCR signaling is critical for activation of 
naive B cells (Bernasconi et al., 2002). Overall response to CpG ODNs is Th1-polarized. 
The immunization of mice with CpG ODN plus an antigen induces Th1 associated IFNγ, 
IL-12 and antigen specific IgG2a and suppresses Th2 associated IL-5 production (Chu et 
al., 1997).  
Central hexameric sequence is Pu-Pu-C-G-Py-Py for mice and Pu-Py-C-G-Pu-Py 
for humans in optimal sequences. Substituting a Purine (Pu) for a Pyramidine (Py), or 
vice versa, significantly reduces or eliminates ODN activity (Krieg et al., 1995; Verthelyi 
et al., 2001). CpG ODNs designed to date can be grouped into i) A/D-type CpG, ii) B/K-
type CpG, and iii) C-type CpG. Additional less well-characterized sequences, which do 
not fit in any of these three groups, are also covered below.  
 
1.3.2.1.  A/D-type CpG ODNs   
This group of CpG ODNs is named as A-ODN by some groups and D-ODN by 
others. It will be referred to as D-ODN hereafter. D-ODNs contain a mixed backbone of 
phosphodiester and phosphorothiote linkages. Generally, a single CpG motif is present in 
the middle of a palindromic sequence with phosphodiester (PO) backbone. The 
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 palindromic sequence is capped by G-runs at both ends. The linkage between the G pairs 
at both ends have phosphorothioate (PS) backbones, which confer increased resistance to 
nucleases. Minimum length of an active D-ODN is 18 bp. Representative sequences are 
given below:  
D19:    5`-GGtgcatcgatgcagGGGGG-3` 
D29:    5`-GGtgcacggtgcagGGGG-3`  
D35:    5`-GGtgcatcgatgcaggggGG-3`  
D no poly(G):   5`-GGtgcttcgatgcaaaaaAA-3`   
D3CG:    5`-GGtcgatcgatcgaggggGG-3` 
ODN 2216:   5’-GGgggacgatcgtcggggGG-3’  
Please note that lowercase letters indicate phophodiester (PO) linkages between bases, 
whereas uppercase letters indicate phosphorothioate (PS)  linkages between bases. 
Underlined bases represent unmethylated CpG dinucleotides.  
 
Any inversion, replacement, or methylation of the CpG abolishes the stimulatory 
activity completely. The polyG ends and central palindromic region of the ODN also 
contribute to D-type activity significantly (Verthelyi et al., 2001). D-ODN has a high 
tendency to spontaneously assemble into higher-order structures, heterogenous particles 
mainly composed of globular (~50nm size) and linear structures (~100nm size), under 
physiological concentration. This structure formation is dependent on the presence of 
poly(G) motifs and on the palindromic region (Costa et al., 2004).  Kerkmann suggests 
that monomeric D-ODN forms a duplex via Watson-Crick base pairing from its 
palindromic regions. Moreover, the poly(G) ends, of which there are four, of the two 
duplexes are linked together via a non Watson-Crick base pairing. This is an interaction 
established between guanosines and is known as “Hoogstein Base Pairing”. The 
interaction between the planar four Gs is called “G-tetrads” and multiple forms of these 
G-tetrads are named as G-quadruplexes. The formation of this structure is given in detail 
in Figure 3. Exposure of G-tetrads to high temperature leads back to formation of their 
monomeric molecules (Kerkmann et al., 2005).  
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Figure 3. G-tetrad links four D-ODN strands for higher-order structure formation 
(Kerkmann et al., 2005). 
 
D-ODN induces high amounts of IFN-α/β directly from pDCs and IFN-γ from 
PBMCs. Maximum activity is reached at 3 µM. They also indirectly induce IFN-γ, IP-10 
from PBMC and NK cell activation strongly. NK cell-mediated IFN-γ production by D-
ODN is IFΝα/β−dependent, and IL12-independent (Krug et al., 2001; Verthelyi et al., 
2001). Moderate levels of costimulatory molecules CD80, CD86 and HLA-DR on pDC 
and B cells are induced. This induction is lower than that of K/B type CpG ODNs (Krug 
et al., 2001). D-ODN stimulates monocytes to mature into CD83+/CD86+ DCs in an IFN-
α-dependent manner (Gursel et al., 2002b). NK cell-mediated cytolytic activity, which is 
a very critical part of innate immunity against intracellular pathogens, also increases 
considerably (Krug et al., 2001). D-type ODN stimulates mouse splenocytes to produce 
moderate IL6, IL-12 and high levels of IFNγ. Interestingly, IFNγ induction by D-type 
ODN reaches maximal activity at 1µg/ml and this activity is reduced at higher 
concentrations (Vollmer et al., 2004). The therapeutic potentials of D-type ODNs are 
hampered by the fact that G-rich containing sequences are problematic during synthesis. 
PolyG-based ODNs lack pharmaceutical attributes due to unpredictable secondary 
structure formation depending on the experimental conditions and nonsequence-specific 
protein binding (Wang et al., 2009). 
 
1.3.2.2.  K/B-type CpG ODNs  
This CpG ODN class is referred to as B or K-type ODNs by different groups. It 
will be referred to as K-ODN hereafter. These are full phosphorothioate backbone ODNs 
with at least one CpG motif. This motif is highly active in humans when it is located 
closer to 5’ end of the sequence and at least one more base upstream of the 5`-CpG motif 
is required. Thymidine in the immediate 5’ position is the most favorable for humans 
(ODN2006). For active CpG ODNs in mice, CpG motif does not have to be at the very 5’ 
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 end (ODN1555, ODN1826). Minimum length of ODN should be 12 bases for sustained 
immune activation (Verthelyi et al., 2001). This type lacks poly-G tails and is believed to 
remain as single stranded linear sequences under physiological conditions (Costa et al., 
2004). Optimal K-ODN sequences are given below:  
1. ODN1826:   5`-TCCATGACGTTCCTGACGTT-3` 
2. ODN1555:  5`-GCTAGACGTTAGCGT-3` 
3. ODN2006:  5`-TCGTCGTTTTGTCGTTTTGTCGTT-3` 
4. K23:  5`-TCGAGCGTTCTC-3` 
K-ODNs trigger IL6 and IgM secretion from B-cells and induce their 
proliferation. They also activate CD19+ B cells by upregulating CD69 (early activation 
marker) and CD25 (late activation marker) (Gursel et al., 2002a). These ODNs are 
superior for pDC maturation and induction of proinflammatory cytokines from pDCs 
than D-type ODNs (Krug et al., 2001). They can also synergize with GM-CSF and 
activate the maturation markers of dendritic cells; MHC II, CD40, and CD83 (Hartmann 
et al., 1999). Poor IFNα induction from pDCs is also characteristic of this type of ODNs, 
whereas it is reported that even this trace amount of IFNα is sufficient enough to induce 
MHC-I cross presentation in DCs (Gray et al., 2007). K-ODN induced IFNγ, IP10 
secretion from PBMC is little also if compared to other ODN types. Spleen cells also 
secrete very high amounts of IL6 and IL-12 in response to K-type ODNs (Krug et al., 
2001; Verthelyi et al., 2001). Mouse-active K-type ODN induces much higher levels of 
nitric oxide (NO) from mouse-macrophage cell line (RAW264.7) in comparison with D-
type ODN (Utaisincharoen et al., 2002).  
 
1.3.2.3.  C-type CpG ODNs  
C-type ODNs have fully phosphorothioate backbone with 5’ CpG sequences 
(‘TCGTCG motif’) and a 12-16 bp palindromic sequence at 3’ end for most optimal 
activity (Vollmer et al., 2004). TCG at 5’ end is necessary for ODN activity and IFNα-
induction capacity is reduced when this motif is shifted towards 3’. Immunostimulatory 
activity of C-ODN depends on the ODN length, the base content and a 5’-TCG. 
Minimum length requirement for optimal activity is 22 bp, where adding poly-T to the 3’ 
end of shorter sequences significantly increases their activity (Jurk et al., 2004). 
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 Palindromic sequence, which is believed to allow duplex formation in an endosomal 
environment, is vital for the immunostimulatory activity of C-type ODN (Krieg, 2006). 
This structrure is illustrated in Figure 4. Immunostimulatory effect is severely reduced in 
similar ODNs lacking palindromic sequences, especially in the context of IFNα 
induction.    
 
 
Figure 4. Duplex formation through palindromic sequences by two monomeric C-ODNs 
ODN2395 (Krieg, 2006). 
 
These ODNs are reported to combine the immunostimulatory activity of D-type 
and K-type ODNs. They directly activate human B cells at a level comparable with K-
ODNs. Furthermore, the production of IFNα from pDC is induced at a higher level 
compared to K-ODNs. They also induce also higher levels of IFNγ, IP-10 from PBMC 
and upregulate activation markers on NK cells better than K-ODN. B-cell activation with 
this type of ODN is pronounced in whole human PBMC stimulation which is not the case 
for K type CpG ODN. IFNα production from pDC seems to have an additive effect on B-
cell activation in whole PBMC stimulation. Depleting pDC from PBMC lowers B-cell 
activation by C-type while this type of reduction does not occur upon K-ODN stimulation 
(Hartmann et al., 2003). 
To sum up, C-ODNs are somewhere between D-ODNs and K-ODNs both 
structurally and immunologically. They induce lower levels of interferon than D-type and 
higher levels than K-type. They also directly activate B cells. Additionally, they form 
duplexes under physiological conditions unlike linear K-ODNs and multimeric D-ODNs.   
 
1.3.2.4.  Other Types of CpG-ODNs  
Several ODNs that do not fit into the previously mentioned classes have also been 
designed. One of them is Y-shaped ODN, which is formed by 3 linear CpG ODNs with 
complementary regions. Its structure is given in Figure 5. This ODN has a phophodiester 
backbone and induces higher levels of IL6 and TNFα from RAW264.7 cells, a mouse 
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 macrophage cell line, than single- and double-strands of same ODNs used at same 
concentrations. It is claimed that this structure increases the efficiency of uptake into cells 
(Nishikawa et al., 2008).  
Another work reported that 3’ extension of phophodiester linear (CpG or non-
CpG ) ODNs with 24 guanine nucleotides turns these sequences into an effective IFNα 
inducer. Whereas shorter ODNs have reduced activity, elongation of the ODNs does not 
result in increased activity. Addition of a CpG motif increases the activity of this ODN. It 
has been shown that polyG addition confers complexation and efficient uptake into 
immune cells similar to the utilization of a complexation agent such as DOTAP (Haas et 
al., 2009).      
 Previous research in our lab has led to the identification of a novel 70-mer 
dendrimeric ODN, which forms uniform-sized nanoparticles with an average size 
distribution of 35 ± 10 nm (Figure 6). It exhibits a higher immunostimulatory potential 
than its linear control. Furthermore, the substitution of CpG dinucleotide with a GpC flip 
completely abolishes its activity in mice (Mammadov, M.Sc. Thesis, 2009). 
 
Figure 5. Y-shaped CpG ODN (Nishikawa et al., 2008). 
 
23 
 
  
Figure 6. Formation of uniform-sized nanoparticles in a novel bifunctional dendrimeric 
ODN, designated as ODN420.  (Mammadov, M.Sc. thesis, 2009) 
 
1.3.3.  Differential Immune Response Mediated by Particulate and Linear CpG 
ODN 
Although both D-type and K-type ODNs contain CpG motifs and initiate their 
effect by signaling through TLR9, the immunologic pathways induced are unique in each 
class. First, D-ODNs have been reported to be localized in different vesicles than those of 
K-ODNs. Moreover, D-ODN is taken up four-fold more efficiently than K-ODN by 
PBMC, where excess concentration of either ODN does not inhibit binding or uptake of 
the other (Gursel et al., 2002a). Collectively, these data suggest that there are different 
mechanisms of uptake for each of these ODNs. Poly-G tail, which confers particulate 
structure in D-ODNs, is thought to be responsible for the more efficient uptake of D-
ODNs in mouse cells (Anderson et al., 2008; de Jong et al., 2007) and human pDC 
(Kerkmann et al., 2006). Second, interferon regulatory factor (IRF)-7 is found to be 
critical for IFNα induction from pDC by D-ODN, as pDCs from IRF7-/- mice are 
unresponsive to D-ODN. D-ODN mediated cytokine production such as IL-12 and IL6 
from cDC (conventional dendritic cells) and K-ODN mediated cDC and pDC activation 
are not affected in IRF7-/- mice (Honda et al., 2005b). The dichotomy of D-type and K-
type ODNs is illustrated in Figure 7. 
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 Two recent works have clarified the differential activities of D- and K-type 
ODNs. Honda et. al. have reported that induction of different cytokines from pDCs by 
two types of ODNs is caused by different localization patterns of K or D-type ODNs in 
pDCs. D-type ODNs are retained for longer periods in the early endosomal vesicles of 
pDCs, whereas K-type ODNs accumulate in vesicles with lysosomal markers (Honda et 
al., 2005a). According to this model, D-ODN interacts with MyD88–IRF-7 complex in 
early endosomes, which results in IRF7-mediated IFNα production. Meanwhile, K-ODN 
activates MyD88-IRAK4/1-TRAF6 complex which activate NF-κB and IRF-5-mediated 
pro-inflammatory cytokine production (Asselin-Paturel and Trinchieri, 2005). Retention 
of D-ODNs in early endosomes is facilitated by their higher-order structure. Artificial 
targeting of K-ODNs to early endosomes can be achieved through making their 
complexes with DOTAP (Honda et al., 2005a). These particulate forms of K-ODNs 
induce IFNα levels comparable with D-ODN (Kerkmann et al., 2005). Recruitment of D-
ODN to early endosomes and its IFNα-inducing capacity are dependent on CXCL16, a 
scavenger receptor only expressed on pDCs but not on B-cells (Gursel et al., 2006). 
Moreover, D-ODNs lacking poly-G tail cannot interact with CXCL16. Identification of 
CXCL16 as a specific co-receptor for D-type ODN might also explain the higher 
efficiency of artificially multimerized ODNs regarding uptake and immune stimulation 
(Haas et al., 2009; Shirota et al., 2001). To date, there is no convincing evidence proving 
that particulate forms of K-ODNs depend on additional recognition by other receptors. 
However, high immunostimulatory potential of nanoparticle-forming CpG-ODNs at low 
concentrations, where free CpG-ODNs are not active, strengthens this hypothesis 
(Anderson et al., 2008; Gursel et al., 2001).  
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Figure 7. Dichotomy of different CpG ODN types delivered to early or late endosomes 
induce innate or adaptive immune responses, respectively, in pDCs. (Williams, 2006) 
 
1.4.  Utilization of CpG ODNs as Therapeutic Agents 
Critical cellular target for CpG ODN therapy are pDCs. Moreover, pDCs from 
CpG-treated donors are able to mount protection in naive recipients. Another TLR9+ cell 
type is B cells, where CpG-ODNs induce production polyclonal immunoglobulins that 
help to eradicate pathogen. NK cells and macrophages are indirectly activated by 
cytokines released from pDCs (Klinman, 2004).  
 In an attempt to define the most optimal sequences, several thousand sequences 
have been synthesized and tested on PBMCs isolated from over 100 donors. It has been 
observed that no single ODN is optimal for all tested individuals. Two strategies are 
suggested to overcome this problem. The first one is to synthesize single ODNs with 
different CpG motifs and the second one is to use mixtures of multiple ODNs with 
different CpG motifs (Leifer et al., 2003). This should be taken into consideration in 
therapeutic approaches with CpG ODNs, which are shown to be effective against 
infectious diseases, cancer, allergy/asthma.  
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 Infectious diseases: CpG ODNs increase resistance of even immunosuppressed, 
newborn and pregnant animals to pathogenic infection. For example, in SIV (retrovirus 
like HIV)-infected macaques, D-type CpG ODN reduces parasitic (leishmania) load up to 
1000-fold. However, CpG treatment increases SIV load in macaques, probably due to the 
activation of infected T cells. As HIV infection does not interfere with innate immunity 
until late stages of the disease, CpG ODN therapy may be used to protect patients from 
other infections (Klinman et al., 2004).  
Moreover, induction of Th1 immunity by CpG ODN suggests that they can be 
used as vaccine adjuvants. CpG ODN + antigen immunization of mice has been shown to 
induce cellular and humoral immunity against antigens more powerfully than antigen 
alone. When K-ODN is adminstered together with AVA (the licensed vaccine against 
anthrax), antigen-specific response increases 6-fold with respect to injection of AVA 
alone (Klinman et al., 2006). Also, CPG 7909 plus vaccine has induced Hepatitis B 
surface antigen (HBsAg)-specific antibody responses (anti-HBs) at earlier time points 
starting from 2 weeks after the initial priming with respect to subjects who received 
vaccine alone. Thus, the development of antigen-specific response is also accelerated 
(Krieg, 2006). 
 
Cancer: The combination of CpG ODN encapsulated in sterically stabilized cationic 
liposome and recombinant interleukin-13 Pseudomonas exotoxin (IL13-PE) is 
significantly effective against human neck and head cancer as xenografts in mice. CpG 
activity is dependent on NK cell activity and IL-13-PE augments its activity (Ishii et al., 
2003). In another study, it has been shown that K-type CpG ODN effectively suppresses 
metastasis of cancer cells, especially if it is administered after surgical removal of the 
primary tumor (Kim et al., 2009). CpG ODN seems to be effective alone for small 
tumors, while CpG therapy should be combined with other therapies like chemotherapy 
for larger tumors (Krieg, 2006).  For now, 4 different CpG ODNs are in clinical trials for 
treatment of 11 different cancers such as breast cancer and melanoma (Krieg, 2008). 
Possible mechanism of CpG-mediated anti-tumor activity is illustrated in Figure 7. 
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Figure 8. Proposed mechanism of CpG ODN-mediated anti-tumor activity (Krieg, 2008). 
 
 
Allergy/Asthma:  Exact mechanism for therapeutic effect of CpG ODN on asthma is not 
clear. Th1 cytokines are not necessary for treatment of allergy (Kline and Krieg, 2008). 
Yet, when CpG ODN is administered two days before challenge with ragweed in 
presensitized mice, allergic lung inflammation is inhibited for a prolonged time (Sur et 
al., 1999). 
 
1.5.  Synthetic DNA Containing Mammalian Telomeric Repeats with 
Immunosuppressive Activity as Another Class of Nanoparticle Forming 
ODNs  
 Although CpG ODN confers a selective advantage to the host by improving 
resistance to a variety of infectious microorganisms, uncontrolled immune activation can 
cause harm by exacerbating inflammatory tissue damage, inducing autoimmune disease 
or toxic shock. During infection or tissue damage, inflammation must be waned and 
terminated with wound healing. Thus, a negative feedback system of innate immune 
activation occurs via several inhibitory signals (Ishii and Akira, 2005). 
 Previous studies indicated that mammalian genome contain some elements 
antagonistic to the immunostimulatory effect of pathogen derived CpG rich DNA. 
Neutralizing or suppressive motifs can selectively block CpG-mediated immune 
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 stimulation (Krieg et al., 1998). Optimal motifs for immunosuppressive ODN are 
surprisingly identical to the telomeric repeats (TTAGGG), which are found in high 
frequency in mammalian DNA but not in bacterial DNA (Gursel et al., 2003). The 
immunosuppressive activity of this motif correlates with its ability to form higher 
structures such as G-tetrads. Suppressive ODN does not interfere with binding or uptake 
of CpG ODN but blocks either TLR9 binding to CpG DNA or the signaling cascade 
upstream of NF-κB  translocation to the nucleus (Gursel et al., 2003; Yamada et al., 
2002). Several groups have identified other G-rich or GC-rich ODNs with 
immunosuppressive activity (Ho et al., 2003; Peter et al., 2008). Reported effects of 
treatment with immunosuppressive ODNs include reduction of Th1 cytokine expression 
and MHC class II expression. 
 The exact molecular mechanism as to how immunosuppressive ODN works is not 
clear. TLR9-dependent effects of immunosuppressive ODNs are proposed to be 
dependent on a putative target that is upstream of inhibitory kinase (IKK) activation 
(Lenert et al., 2001). It has been shown to inhibit Th1 differentiation by blocking IFN-γ 
and IL12-mediated signaling (Shirota et al., 2004). In one study, while Th1 responses are 
suppressed, it has been observed that Th2 responses are enhanced (Ho et al., 2003). Some 
immunosuppressive ODNs specifically inhibit TLR9 signaling (Peter et al., 2008). 
Meanwhile, several TLR9-independent effects have been observed upon treatment with 
other suppressive ODNs. It has been shown that treatment with an immunosuppressive 
ODN renders TLR9-deficient bone marrow derived macrophages more susceptible to S. 
typhimurium infection. This effect is attributed to the observation that immune responses 
to TLR2 ligand Pam3Cys are also suppressed upon treatment with suppressive ODN 
(Trieu et al., 2009). While it can be suggested that these ODNs may compromise the 
immune system of the host, these agents pose great therapeutic potentials as anti-
inflammatory agents in autoimmune diseases. Suppressive ODN treatment has caused 
protection of mice from LPS-induced endotoxic shock. Suppressive ODN does not inhibit 
LPS-induced cell activation or reduce LPS-dependent production of IL6, IL-12 and TGF-
β. Yet,  it acts at a later stage of LPS-induced immune activation and prevents 
phosphorylation of STAT1 and STAT4 by binding to it (Shirota et al., 2005).  
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 1.6.  Utilization of Immunosuppressive ODNs as Therapeutic Agents 
 
Arthritis: Arthritis is the most common rheumatic disease and characterized by 
progressive destruction, deformity and disability of the joints. There are two experimental 
models of arthritis: CpG DNA-induced reactive arthritis and collagen-induced arthritis. 
Early administration of suppressive ODN reduces severity of arthritis in both models by 
reducing autoantibodies and IFNγ production by reactive T cells (Dong et al., 2004; 
Zeuner et al., 2002). 
 
Systemic lupus erythematosus (SLE): Lupus is a systemic autoimmune disease 
characterized by the production of antinuclear autoantibodies, immune complex-mediated 
glomerulonephritis and various types of end-organ damage. Early administration of 
suppressive ODN controls a murine lupus model, in which female NZB x NZW mice 
progressively develop immunologic and clinical manifestations of disease that closely 
resemble SLE in humans (Dong et al., 2005). 
 
Pulmonary inflammation: Silica-containing dust particles induce silicosis, an 
inflammatory disease of the lungs characterized by the infiltration of macrophages and 
neutrophils into the lungs and the production of proinflammatory cytokines, chemokines 
and reactive oxygen species (ROS). In vivo studies show that pretreatment with 
suppressive ODN improves the survival of mice exposed to silica as manifested by fewer 
infiltrating cells, less cytokine/chemokine production and lower levels of ROS (Sato et 
al., 2008). 
 
Multiple sclerosis: Multiple sclerosis is an autoimmune disorder, in which components 
of the myelin sheath are targeted by the inflammatory strike resulting in demyelination 
and neurodegeneration. Paralysis, sensory disturbances, lack of coordination and visual 
impairment are common symptoms. Experimental autoimmune encephalomyelitis (EAE) 
is the animal model and can be induced by neuroantigens such as MOG or PLP. In an 
EAE model, combining a myelin cocktail plus IL-4-tolerizing DNA vaccine with a 
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 suppressive G-rich ODN induces a shift of the autoreactive T cell response toward a 
protective Th2 cytokine pattern and reduces disease severity (Ho et al., 2005). 
 
Uveitis: Uveitis is an autoimmune disease characterized by ocular inflammation. In a 
murine model, uveitis can be induced by interphotoreceptor retinoid-binding protein, a 
retinal antigen. Suppressive ODN treatment inhibits the retinal antigen-specific cytokine 
production and lymphocyte proliferation in mice immunized with IRBP (Fujimoto et al., 
2009).
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 2. AIM OF STUDY 
 CpG ODNs are a promising class of DNA-based drug candidates. They directly 
stimulate human B cells and plasmocytoid dendritic cells, induce the production of Th1 
and proinflammatory cytokines and trigger the maturation of antigen-presenting cells. 
Moreover, the synthesis of these drug candidates is cheaper with respect to conventional 
protein-based agents and well-established under GMP (good manufacturing practice) 
conditions. CpG ODNs are already in clinical trials for different diseases.  
K-type CpG ODNs have phosphorothioate backbones and induce high levels of 
IL6, IL12, TNFα and IgM levels. They remain single-stranded in body fluid. On the 
other hand, D-type CpG ODNs have mixed backbones. The poly-G tails on 5’ end and 3’ 
end are made of phosphorothioate backbones while the central regions contain the natural 
phosphodiester backbone. D-type CpG ODNs are unique in the manner that they induce 
anti-viral type I IFN production and higher levels of monocyte maturation into DCs. 
Accumulating data indicate that these effects are at least partially attributed to their 
ability to be retained longer in the early endosomes by forming multimeric structures. 
Previous studies in our lab have established the characterization of a novel CpG 
ODN. This ODN, designated as ODN420, is synthesized by linking seven ODN1466 
sequences by two bifunctional linkers. ODN1466 is a K-type ODN. Yet, ODN420 
spontaneously forms uniform nanoparticles like D-type ODNs and exhibits higher 
immunostimulatory activity like K-type ODNs. Only ODN420 with PS backbone has 
been used in these studies. Moreover, the effect of ODN420 has been tested only on 
primary cell culture obtained from mouse splenocytes. Its in vivo activity and its activity 
on human cells have not been studied yet. To date, the activity of K-ODN is assessed by 
PS backbones. When PO backbone is used, substantial loss in immunostimulatory 
potential has been observed. While PS linkage yield more nuclease resistant ODNs, it is 
very expensive than PO backbone. Considerable research efforts are being made to 
develop PO sequences displaying PS characteristics.   
In this context, the first part of this study investigates the immunostimulatory 
potential of ODN420 with different (PS or PO) backbones in mouse splenocytes. These 
activities are compared to several ODN classes. The activity of nanoparticle ODNs on 
human PBMC is determined with various assays. Next, its immunostimulatory potential 
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 is evaluated by an in vivo experiment. Finally, the potential of ODN420 as a vaccine 
adjuvant and as an anti-cancer agent are evaluated in two different in vivo studies. The 
mechanism and activity of another class of nanoparticle forming ODN, ODN-A151, 
which exhibits immunosuppressive activity, are also evaluated in the immunization 
experiment.  
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 3. MATERIALS & METHODS 
 
3.1.  MATERIALS 
 
3.1.1.  Reagents 
All oligodeoxynucleotides (ODNs) are synthesized at AlphaDNA (Canada) or kind 
gifts from Dennis Klinman (NCI/NIH, USA). ODNs are devoid of any detectable LPS 
contamination as judged by Limulus Ameobyte Lysate (LAL) assay. Bases written in 
lower case represent phosphodiester linkages whereas bases written in upper cases 
represent phosphorothioate linkages. Stimulatory CpG motifs and the control GpC motifs 
in the control ODNs are underlined. ODN sequences are given below: 
A151   (24-mer) : 5`-TTAGGTTAGGTTAGGTTAGG-3` 
C-A151   (24-mer) : 5`-TTCAAATTCAAATTCAAATTCAAA-3` 
1466   (10-mer) : 5`-TCAACGTTGA-3` 
1471   (10-mer) : 5`-TCAAGCTTGA-3` 
K23   (12-mer) : 5`-TCGAGCGTTCTC-3` 
D35   (20-mer) : 5`-GGtgcatcgatgcaggggGG-3` 
D3(CG)   (20-mer) : 5`-GGtcgatcgatcgaggggGG-3` 
I-127    (20-mer) : 5`-GGtgcatgcatgcaggggGG-3` 
Linear-7x-1466 (70-mer) : 7 x 1466 (linear sequence) 
Linear-7x-1471 (70-mer) : 7 x 1471 (liner sequence) 
420   (70-mer) : 7 x 1466 (dendrimeric sequence linked via two symmetric 
bifunctional linkers, please see Figure 9) 
421   (70-mer) : 7 x 1471 (dendrimeric sequence linked via two symmetric 
bifunctional linkers, please see Figure 10) 
422   (90-mer) : 9 x 1466 (dendrimeric sequence linked via a symmetric 
bifunctional linker and then via a trifunctional linker, please see Figure 11) 
423   (90-mer) : 9 x 1471 (dendrimeric sequence linked via a symmetric 
bifunctional linker and then via a trifunctional linker, please see Figure 12) 
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 Lipopolysachharide (LPS) isolated from E. coli is purchased from Sigma (USA) and 
R848 is purchased from Invivogen (USA). All primers for PCR are purchased from 
AlphaDNA (Montreal, Canada). ELISA reagents including paired antibodies for 
cytokines, recombinant antibodies, streptavidine-alkaline phosphatase (SA-AKP) and p-
nitrophenyl phosphate disodium salt (PNPP)-substrate for alkaline phosphatase are 
purchased from Endogen/Perbio, Pierce (USA) unless otherwise stated. 
 
 
Figure 9. ODN420: Schematic representation of the ODN420 formation via the use of 
two bifunctional linkers at the 3`-end of ODN 1466 sequences. 
 
 
Figure 10. ODN421: Schematic representation of the ODN421 formation via the use of 
two bifunctional linkers at the 3`-end of ODN 1471 sequences. 
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Figure 11. ODN422: Schematic representation of the ODN422 formation via the use of a 
bifunctional linker for G=2 and a trifunctional linker for G=3 at the 3`-ends of ODN 1466 
sequences. 
 
Figure 12. ODN423: Schematic representation of the ODN423 formation via the use of a 
bifunctional linker for G=2 and a trifunctional linker for G=3 at the 3` ends of ODN 1471 
sequences. 
 
3.1.2.  Cell Culture Media, Buffers and Other Standard Solutions 
DNAse/RNAse free water, RPMI1640 and low glucose DMEM media, Na-pyruvate, 
HEPES, L-glutamine, penicillin/streptomycin, non-essential amino acid solution, FBS are 
from Hyclone PerBio (USA). 
Components of various culture media and different buffers are given in detail in the 
Appendix A. 
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 3.2.  METHODS 
3.2.1.  Cell Culture 
3.2.1.1.  Cell Lines 
 Human hepatocellular carcinoma cell line Huh7 (ATCC) is cultured with 10% 
FBS supplemented DMEM. Adherent cells are passaged when they reach 90% 
confluency with fresh media following trypsinization and washing. 
  
3.2.1.2.  Single Cell Splenocyte Preparation 
Mice are euthanized by cervical dislocation. Spleens are removed with sterile 
instruments and put into 3 ml 2% FBS supplemented regular RPMI media in 6-well 
plates. In sterile cell culture conditions, single cell suspensions are obtained by smashing 
spleens with the back side of a sterile syringe in media with circular movements. 
Homogenous part of media is collected by using sterile plastic pasteur pipettes while cell 
clumps belonging to fibrous or connective tissue are left. Cells are centrifuged at 1500 
rpm for 10 minutes at room temperature. Medium is sucked cell pellet is gently 
resuspended in 10 ml fresh media and centrifuged at the same conditions. These washing 
steps are repeated twice to remove remaining tissue debris. At the end of last washing 
step, cells are resuspended in 10 ml 5% FBS supplemented regular RPMI and counted.  
 
3.2.1.3.  Peripheral Blood Mononuclear Cell (PBMC) Isolation from Whole 
Blood 
Blood samples from healthy donors are transferred to 50 ml tubes containing Naq-
Citrate, EDTA or Heparin. New 50 ml tubes are filled with 15 ml Biocoll or Histopaque 
separating solution (Biochrom AG, Germany and Sigma USA respectively). 22.5 ml 
blood is slowly layered on top of Histopaque without disturbing layers. Samples are 
centrifuged at 1800 rpm for 30 minutes at break off setting. The cloudy buffy coat in the 
middle erythrocytes and basophils is taken with sterile Pasteur pipettes and transferred to 
a new tube. 2% FBS supplemented regular RPMI media is added until total volume 
reaches 50 ml. Samples are centrifuged at 1800 rpm for 10 minutes. Medium is sucked 
cell pellet is gently resuspended in 10 ml fresh media and centrifuged at the same 
conditions. These washing steps are repeated twice to remove remaining cell debris. At 
37 
 
 the end of last washing step, cells are resuspended in 10 ml 5% FBS supplemented 
regular RPMI and counted. 
 
3.2.1.4.  Cell Counting and Distribution 
After cells are resuspended in 10 fresh media as indicated above, 10 µl from these 
cell suspensions is taken and diluted 10 fold with 90 µl medium to reduce the cell number 
in the final 100 µl solution. 10 µl from diluted solution is placed on Neubaer cell 
counting chamber. Cells in 4 corners (composed of 16 small squares) with 1mm2 area 
were counted under light microscope (Figure 13).       
 
Figure 13. Neubaer cell counting chamber 
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 The depth between coverslip and cell counting chamber is 0.1 mm. Thus, each 1 
mm2 area holds a volume of 0.1 mm3. So, the number of cells/ml can be obtained from 
the equation given below:  
 
        Total cell number in 4 big squares       x 10 x 104 = number of cells per ml.  
                                 4                               dilution factor            
              
number of cells per 0.1 mm3
 
After total cell number is determined, original cell stock is centrifuged and 
resuspended in an appropriate volume of 5% FBS supplemented oligo medium if cells are 
to be stimulated with ODNs. If stimulation with ODNs is not to be performed, cells are 
resuspended in 5% FBS supplemented regular medium. Working cell concentration is 
adjusted to 4x106 cells/ml for ELISA experiments, 1x107cells/ml for RNA extraction and 
2x106 cells/ml for FACS analysis unless otherwise stated.  
 
3.2.1.5.  Stimulation Protocols 
For stimulation in 96-well cell culture plates, 100 µl of 4x106 cells/ml stock 
(400,000 cells/well) are transferred to 96-well plates. Total volume is adjusted to 200 µl 
with ODNs in 100 µl 5% FBS supplemented oligo medium. Unless otherwise stated, final 
concentration of ODNs is 1 µM. Stimulations are performed in triplicate wells for each 
indicated treatment (Gursel et al., 2001). Supernatants are collected after 24-48h for 
analysis of secretion of various cytokines. For gene expression studies and FACS 
analysis, 500 µl of original cell stock (5x106 cells for gene expression studies and 1x106 
cells for FACS analysis) is transferred to 15 ml tubes. Total volume is completed to 1 ml 
with specific ODNs in 500 µl 5% FBS supplemented oligo medium. Unless otherwise 
stated, final concentration of ODNs is 1 µM.  For gene expression studies, incubation 
periods are 2-8 hours while incubation periods are 6-72 hours for FACS analysis 
depending on the marker to be examined. Tubes are left in tilted position with loosened 
caps to allow airflow and lids of 96-well plates are closed during the incubation period in 
CO2 incubator. 
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 3.2.2.  Fluorescence Activated Cell Sorting (FACS) 
 
3.2.2.1.  Cell Surface Marker Staining 
 Cells are centrifuged at 1500 rpm for 7 minutes at the end of the incubation 
periods. Supernatant is sucked. The protocol is a slightly modified version of two 
previously published protocols (Gursel et al., 2006; Gursel et al., 2002b). Briefly, pellet is 
disturbed by applying mechanical force in one direction following centrifugation by 
using a pin rack. If cells are to be stained and analyzed later, cells are fixed in 100 µl 
fixation medium (Caltag, Austria) and transferred to 1.5 ml tubes. Cells are incubated in 
dark at room temperature for 15 minutes. 1 ml PBS-BSA-Na azide is added into each 
tube to wash cells. Cells are spun at 2000 rpm for 5 minutes in microcentrifuge. 
Supernatant is discarded and the washing step is repeated. At the end of the second 
washing step, PBS-BSA-Na azide is discarded and cells are incubated in 50 µl PBS-
BSA-Na azide containing 4-6 µl of fluorochrome-associated cell surface marker. 
Antibodies against the following cell markers for human cells are used throughout this 
thesis: CD123-PE, CD86-PE/Cy5, CD19-PE/Cy5 (BD Pharmingen, USA), BDCA2-
FITC (Miltenyi Biotech, USA) and CD83-PE (Caltag, Austria). If cells are to be stained 
and analyzed immediately, fixation is not required. The cells can be stained in 50 µl PBS-
BSA-Na azide containing 4-6 µl of fluorochrome-associated cell surface marker. The 
remaining steps are similar but all steps are performed on ice if cells are not fixed. Cells 
are washed twice, resuspended in 500 µl PBS-BSA-Na azide, transferred to FACS tubes 
and analyzed in FACSCalibur (BD, USA). 
 
3.2.2.2.  Intracellular Cytokine Staining 
 Here, a modified version of a previously reported method is used (Gursel et al., 
2002a). For TNFα staining, Brefeldin A is immediately added to tubes and tubes are 
incubated for 4.5 hours. Cells are centrifuged at 1500 rpm for 7 minutes at the end of the 
incubation periods. Supernatant is sucked. Pellet is disturbed by applying mechanical 
force in one direction. Cells are fixed in 100 µl fixation medium (Caltag, Austria) and 
transferred to 1.5 ml tubes. Cells are incubated in dark at room temperature for 15 
minutes. 1 ml PBS-BSA-Na azide is added into each tube to wash cells. Cells are spun at 
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 2000 rpm for 5 minutes. Supernatant is discarded and the washing step is repeated. At the 
end of the second washing step, PBS-BSA-Na azide is discarded and cells are incubated 
in 50 µl permeabilization medium (Caltag, Austria) containing 2-4 µl of fluorochrome-
associated antibodies against human intracellular cytokines TNFα-PE and (BD 
Pharmingen). When TNFα-PE is not available, each tube is first incubated with 0.5 µg 
biotinylated antibody against TNFα (Pierce, USA) in 50 µl permeabilization medium in 
dark for 30 minutes. Then, after washing, cells are incubated with 1:200 diluted SA-PE 
(BD Pharmingen) in 50 µl permeabilization medium in dark for 30 minutes. Cells are 
washed twice, resuspended in 500 µl PBS-BSA-Na azide, transferred to FACS tubes and 
analyzed in FACSCalibur (BD, USA).  
 
3.2.2.3.  Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Assay 
The method is from a previously published protocol (Parish et al., 2009). After 
PBMC is isolated, 1.5 million cells/treatment groups are transferred to 50 ml tubes. Total 
volume is completed to 50 ml with warm PBS. Cells are spun at 1800 rpm for 10 
minutes. Medium is sucked and cells are resuspended in warm PBS in a working 
concentration of 1x107 cells/ml. Equal amount of warm PBS containing 2 µM CFSE is 
added on top of cells so that final concentration of CFSE is 1 µM for 5x106 cells/ml. 
Cells are gently pipetted for equal distribution of CFSE and incubated at 37°C for 10 
minutes. 30 ml 5% FBS supplemented regular medium is added for washing. Cells are 
spun at 1800 rpm for 10 minutes and medium is sucked. Cells are resuspended in 5% 
FBS supplemented oligo medium in a working concentration of 3x106 cells/ml. 0.5 ml is 
transferred to 24-well plate and the regular stimulation protocol is performed by adding 
0.5 ml oligo medium containing appropriate concentration of ODNs. Samples are 
incubated for 3 days and the cell surface marker staining protocol is performed with the 
surface marker of interest as mentioned above. 
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 3.2.3.  ELISA 
 
3.2.3.1.  Cytokine ELISA 
At the end of the incubation periods of cells stimulated in 96-well tissue culture 
plates, plates are spun at 1500 rpm for 6 minutes and 170 µl supernatant is collected from 
each plate. The ELISA protocol is a modified version of a previously reported protocol 
(Gursel, 2003). Briefly, supernatants can be stored at -20oC. 96-well PolySorp plates (F96 
Nunc-Immunoplate, NUNC, Germany) or Immulon 2B plates (Thermo Labsystems, 
USA) are coated with monoclonal antibodies against mouse and human cytokines IFNγ 
and IL6. 50 µl from antibody solution (10 µg/ml for monoclonal antibodies against 
mouse IFNγ and IL6, 4 µg/ml for monoclonal antibody against human IL6, 10 µg/ml for 
monoclonal antibody against human IFNγ) is added to each well. Plates are incubated at 
room temperature for 5 hours or at 4°C for overnight. Coating antibody is spilled. Wells 
are blocked with 200 µl blocking buffer for 2 h at room temperature. Plates are washed 
with ELISA wash buffer 5 times with 5 minute incubation intervals after each wash and 
then rinsed with ddH2O for 3 times. Plates are dried by tapping (same washing procedure 
is repeated in the subsequent steps). Supernatants of cultured cells and recombinant 
proteins are added (50 µl/well from both). Starting concentration for mouse IL6 and 
mouse IFNγ recombinant cytokines are 2000ng/ml and 500ng/ml, respectively. Starting 
concentrations for human IL6 and IFNγ recombinant cytokines are 1000 ng/ml and 500 
ng/ml, respectively. Recombinant cytokines are serially two-fold diluted with 50 µl 1X 
PBS (for 11 times). Plates are incubated for 2-3 hours at room temperature or overnight at 
4°C. Plates are washed as explained above. Then, 50 µl from 0.5 µg/ml biotinylated-
secondary antibody solution (original biotinylated antibody stock is 1/1000 diluted in T-
Cell Buffer, please see Appendix I for details) is added to each well. Plates are incubated 
with biotinylated antibodies overnight at 4°C. Plates are washed as previously explained. 
50 µl from 1:5000 diluted streptavidin-alkaline phospahatase solution (SA-AP in T-cell 
buffer must be prepared one day prior to its use and kept at 4°C) is added to each well. 
SA-AP is further incubated for 1 hour at room temperature. The washing step is repeated. 
One PNPP tablet is added to 4 ml ddH2O and 1 ml PNPP substrate for each plate and 50 
µl of PNPP substrate is added to each well. Yellow color formation is followed and OD 
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 at 405 nm is analyzed with ELISA reader for several readings until recombinant cytokine 
standards reach a four parameter saturation and S-shaped curve is obtained. Each sample 
should be triplicate in cytokine ELISA. Each cytokine level for the samples are calculated 
using corresponding standard curves.  
 
3.2.3.2.  IgG anti-OVA ELISA 
IgG ELISA is very similar to cytokine ELISA protocol except for a few steps. 
The method is from a previously published report (Gursel et al., 2001). All incubation 
times and washing steps are similar with cytokine ELISA. Immulon 1B 96-well plates 
(Thermo Labsystems, USA) are used. Each well is coated with 50 µl of 10 µg/ml OVA 
(Pierce, USA) diluted in 1X PBS. Blocking and washing steps are same as cytokine 
ELISA please see above section for details). Instead of supernatants, serum for each 
animal is placed on the first row in 1/7 titration (10 µl serum is diluted with 60 µl 1X 
PBS). All wells except for the 1st row are filled with 52.5 µl 1X PBS and 4-fold serial 
dilution is performed on vertical axis by transferring 17.5 µl from above well to bottom 
well (total of 7 dilutions are carried out). Antibodies against mouse IgG, IgG1, IgG2a, 
IgG2b (Southern Biotech, USA) are directly linked with AP. So, SA-AP incubation step 
is not performed. AP-linked IgG antibodies (1 mg/ml) are 1:3000 diluted in T cell buffer 
and again prepared one day prior to their use. After the addition of PNPP, yellow color 
formation is followed and OD at 450 nm is analyzed with ELISA reader for several 
readings. Titrations at which similar ODs can be observed are used to compare the level 
of each IgG subclass titers between different treatment groups. 
 
3.2.4.  Determination of Gene Expression at mRNA Level 
 
3.2.4.1.  Total RNA Isolation 
Cells are centrifuged at 1500 rpm for 7 minutes at 4°C. Supernatant is discarded 
and cells are lysed with 1 ml Trizol, a mono-phasic solution of phenol and guanidinium 
thiocyanate (Invitrogen). Cell lysates can be stored at -80°C or can be transferred into 1.5 
ml tubes for further RNA purification steps. All subsequent steps are performed on ice 
and all centrifugation steps are done at 4°C. For each 1mL Trizol used, 200 µl chloroform 
43 
 
 is added to each tube and tubes are shaken vigorously for 15 seconds. After they are 
incubated at room temperature for 3 minutes, samples are centrifuged at 13200 rpm for 
15 minutes at 4°C. Following centrifugation, 550-600 µl of the clear upper aqueous phase 
is transferred to a new tube and 500 µl isopropanol is added to each tube and samples are 
mixed by gentle inversions to allow homogeneous mixing while avoiding uncontrolled 
RNA strand breaks. Then, tubes are incubated at room temperature for 10 minutes and 
centrifuged at 13200 rpm for 15 minutes. Supernatant is sucked and the pellet is gently 
washed with 1 ml of 75% ethanol. Samples are centrifuged at 8000 rpm for 7 minutes. 
Again, supernatant is discarded and pellet is gently washed with 1ml >99.9% ethanol. 
After centrifugation at 8000 rpm for 7 minutes, ethanol is discarded and pellet is dried 
under laminal flow hood in a tilted position. Dry pellets are dissolved in 20 µl 
RNase/DNase free ddH2O. The OD measurements at 260 and 280 nm wavelengths are 
obtained with the spectrophotometer NanoDrop® ND-1000 (NanoDrop Technologies, 
USA). Purified total RNA samples are expected to have A260/A280 value between 1.8 to 
2.0 OD ratio which indicates minimal contamination with DNA, protein, polysaccharides 
or phenol. RNA samples are stored at -80°C for further use. 
 
3.2.4.2.  cDNA Synthesis 
cDNAs are synthesized from total RNA samples with the cDNA synthesis kit 
(Finnzymes) according to the manufacturers’ protocol. 1µg total RNA is mixed with 1 µl 
of Oligo(dT)15 primer (100 ng)  primer and total volume is completed to 8 µl with 
RNase DNase free H2O in 0.2 ml PCR tubes. Tubes are pre-denatured at 65°C for 5 
minutes in MJ Mini thermocycler (BIO-RAD, USA) and then spun down. 10µl RT 
Buffer (includes dNTP mix and 10 mM MgCl2) and 2µl M-MuLV RNase H+ reverse 
transcriptase (includes RNase inhibitor) are added to the mixture. Tubes are incubated at 
25°C for 10 minutes, 40°C for 45 minutes and 85°C for 5 minutes. cDNA samples are 
stored at -20°C for further use. 
 
3.2.4.3.  PCR 
Designed primers are developed with Primer3 Input v.0.4.0 program 
(http://frodo.wi.mit.edu/primer3/input.htm) and Primer Designer Version 2.0 using the 
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 cDNA sequences of human and mouse genes available at the Ensembl database. Each 
primer pair is blasted (http://www.ncbi.nlm.nih.gov/BLAST/) against the mouse or 
human genome. Detailed information on mouse and human primers are given in Table 6 
and Table 7, respectively. 
 
Table 6. Sequences and product sizes of the primers for mouse genes. 
Primer  Sequence Product 
Size  
m β-actin 
 
Forward 
Reverse 
5’-GTATGCCTCGGTCGTACCA-3’ 
5’-CTTCTGCATCCTGTCAGCAA-3’ 
450 bp 
m TLR-3 Forward 
Reverse 
5’-GGGGCTGTCTCACCTCCAC-3’ 
5’-GCGGGCCCGAAAACATCCTT-3’ 
250 bp 
m TLR-7 Forward 
Reverse 
5’-TTAACCCACCAGACAAACCACAC-3’ 
5’-TAACAGCCACTATTTTCAAGCAGA-3’ 
700 bp 
m TLR-9 Forward 
Reverse 
5’- GATGCCCACCGCTCCCGCTATGT-3’ 
5’-TGGGGTGGAGGGGCAGAGAATGAA-3’ 
430 bp 
m IFNg Forward 
Reverse 
5’-GCGTCATTGAATCACACCTG-3’ 
5’-ATCAGCAGCGACTCCTTTTC-3’ 
195 bp 
m IL-15 Forward 
Reverse 
5’-CATCCATCTCGTGCTACTTGTGTT-3’ 
5’-CATCTATCCAGTTGGCCTCTGT-3’ 
126 bp 
m IP-10 Forward 
Reverse 
5’-GCCGTCATTTTCTGCCTCAT-3’ 
5’-GCTTCCCTATGGCCCTCATT-3’ 
127 bp 
m CD40 Forward 
Reverse 
5’-GTCATCTGTGGTTTAAAGTCCCG-3’ 
5’-AGAGAAACACCCCGAAAATGG-3’ 
91 bp 
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 Table 7. Sequences and product sizes of the primers for human genes. 
Primer  Sequence Product Size  
h GAPDH 
 
Forward 
Reverse 
5’-ACCACCATGGAGAAGGCTGG-3’ 
5’-CTCAGTGTAGCCCAGGATGC-3’ 
532 bp 
h TLR-3 Forward 
Reverse 
5’-TCGAGAGTGCCGTCTATTTG-3’ 
5’-CAACTTCATGGCTAACAGTGC-3’ 
199 bp 
h TLR-7 Forward 
Reverse 
5’-ACGAACACCACGAACCTCAC -3’ 
5’-GGCACATGCTGAAGAGAGTTAC- 3’ 
725 bp 
h TLR-9 Forward 
Reverse 
5’-GAAGGGACCTCGAGTGTGAA-3’ 
5’-GTAGGAAGGCAGGCAAGGTA-3’ 
188 bp 
h MxA-1 Forward 
Reverse 
5’-TCGGCAACAGACTCTTCCAT-3’ 
5’-TTCAGGAGCCAGCTGTAGGT-3’ 
191 bp 
h MxA-2 Forward 
Reverse 
5’-TGAAATAGGCATCCACCTGA-3’ 
5’-TTGAAGCAGCCAGGAATAGC-3’ 
169 bp 
h IFNα Forward 
Reverse 
5’-GGAGTTTGATGGCAACCAGT-3’ 
5’-CTCTCCTCCTGCATCACACA-3’ 
192 bp 
h IFNβ Forward 
Reverse 
GCTCTCCTGTTGTGCTTCTCCACTACAGC 
CTGACTATGGTCCAGGCACAGTGACTGT
ACTCC 
 
476 bp 
h IFNγ Forward 
Reverse 
5’-TGGAGACCATCAAGGAAGACA-3’ 
5’-GCGACAGTTCAGCCATCAC-3’ 
156 bp 
h TNFα Forward 
Reverse 
5’-CCCGAGTGACAAGCCTGTAG-3’ 
5’-GATGGCAGAGAGGAGGTTGAC-3’ 
271 bp 
 
All reagents are mixed and subjected to optimal PCR conditions for specific 
primer set in MJ Mini thermocycler (Biorad). PCR mixtures are prepared according to the 
protocol in Table 8. Running conditions for mouse primers are given in Table 9 and those 
for human primers are given in Table 10. PCR products are kept at 4°C until they are 
loaded on agarose gel. 
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 Table 8. PCR reactants 
Reaction Ingredients  Volume 
2x DyNAzyme™ II PCR Master Mix* 12,5 µl 
DNAse/RNAse free  H2O   9 µl 
Forward primer   1 µl (10pmol) 
Reverse primer  1 µl (10pmol) 
cDNA  1,5 µl 
Total  25 µl 
*2x DyNAzyme™ II PCR Master Mix includes 0.04 U/µl DyNAzyme™ II DNA 
Polymerase, 20 mM Tris-HCI (pH 8.8 at 25°C), 3  mM MgCl2, 100 mM KCl, stabilizers 
and 400 µM of each dNTP. 
 
Table 9. PCR conditions for mouse primers 
PCR Step 
mβ‐actin, 
mIP10, 
mTLR3, 
mTLR7 
mTLR9   mIFNγ, 
mIL15  mCD40 
Initial Denaturation  ‐  94°C, 2’  ‐  95°C, 3’ 
Denaturation  94°C, 30’’  94°C, 30’’  94°C, 30’’  95°C, 30’’ 
Annealing  55°C, 30’’  64°C, 30’’  60°C, 30’’  62°C, 30’’ 
Extension  72°C, 30’’  72°C, 1’  72°C, 30’’  72°C, 45’’ 
Number of cycles  35  35  35  35 
Final Extension  72°C, 5’  72°C, 10’  72°C, 5’  72°C, 7’ 
 
Table 10. PCR conditions for human primers 
PCR Step 
 hIFNα, 
hIFNβ, 
hIFNγ, 
hMxA‐1, 
hMxA‐2 
hTLR3,  
hTLR9 
hTLR7, 
hGAPDH  hTNFα 
Initial Denaturation  95°C, 7’  95°C, 7’  ‐  ‐ 
Denaturation  95°C, 30’’  95°C, 30’’  94°C, 10’’  94°C, 10’’ 
Annealing  60°C, 30’’  61°C, 30’’  63°C, 20’’ 
65°C, 
‐0.2°C/cycle, 
20’’ 
Extension  72°C, 30’’  72°C, 30’’  ‐  ‐ 
Number of cycles  35  35  35  35 
Final Extension  72°C, 3’  72°C, 3’  72°C, 1’  72°C, 1’ 
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 3.2.4.4.  Agarose Gel Electrophoresis and Quantification of Band Intensities 
 1.5% agarose gel is prepared with 1X TAE buffer and final concentration of 
ethidium bromide is 1 µg/ml. 2 µl loading dye is mixed with 10 µl PCR product. 10 µl of 
mixture is loaded to each well. 3 µl of 105 ng/µl DNA ladder with 100-1000bp range or 
low range DNA ladder with 50-1000bp range (Jena Biosciences) is loaded on an empty 
well and used as a marker. 80V is applied for 45 minutes and the gel is visualized under 
UV transilluminator (Vilber Lourmat, France). The gel exposure time is kept fixed at 0.1 
second for each run. Band intensity analysis is performed with BIO-PROFILE Bio-1D 
V11.9 sofware. Band intensity for each product is measured and background intensity is 
subtracted from this value. Blanked intensities for each product are divided by blanked 
house-keeping gene values (β-actin for mouse and GAPDH for human samples) to 
normalize resulting quantitative data or directly compared. 
 
3.2.5.  In vivo Experiments 
 
3.2.5.1.  Maintenance of the Animals 
 Adult male or female BALB/c, C57/BL6 or T-cell deficient nude mice (8-12 
weeks old) are used for the in vivo experiments. The animals are kept in the animal 
holding facility of the Department of Molecular Biology and Genetics at Bilkent 
University under controlled ambient conditions (22°C ± 2) regulated with 12-hour light 
and 12-hour dark cycles. They are provided with unlimited access of food and water. All 
experimental procedures have been approved by the animal ethical committee of Bilkent 
University (Bil-AEC).  
 
3.2.5.2.  Immunization Protocol with Specific ODNs and OVA 
Three to five adult male C57/BL6 mice per group are injected intraperitoneally 
with 15 µg of ODN-D35 or ODN-420 and 7.5 µg of OVA in combination with or without 
15 µg A151. The protocol is given in detail in Figure 14. Fourteen days later, boosting 
injection is performed i.p. with the same ODN and OVA combinations. Animals are bled 
one day before each injection and on the twenty-seventh day. Mice blood is incubated at 
37°C for 1.5 hours, the clot is discarded and then the remaining part is spun at 13200 rpm 
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 for 1 minute. The mice sera for background, primary and secondary bleedings was 
collected in 96 well plates and stored at -20°C for further use. Animals are sacrificed on 
day twenty-eight and their spleens are removed. From the half of the spleen single cell 
splenocytes are prepared and incubated for 42h to assess IFNγ secretion between 
different treatment groups and from the rest of the spleens total RNA is extracted and is 
studied for the expression of several Th1, pro-inflammatory and inflammatory 
cytokines/chemokines by PCR. 
 
 
 
Figure 14. Immunization schedule for in vivo vaccination. 
 
 
3.2.5.3. Tumor Xenograft Model 
 5 x 106 Huh7 cells in 250 µl sterile 1X PBS are injected subcutaneously to adult 
T-cell deficient nude mice (3-5/group). Since tumor formation is heterogeneous and some 
nude mice develop tumors later than 3 weeks, the day on which a palpable tumor forms is 
considered as day 0. Three doses of 100 µg of ODN-420 or ODN-A151 are injected 
intratumorally with one day-on and one day-off treatment starting from day 3 post-
palpable tumor formation. Tumor dimensions are recorded daily as width, height and 
length by a caliper and calculated as mm3. 
 
3.2.6.  Statistical Analysis 
Statistical analysis is performed in SigmaSTAT 3.5 software. Students’ t-test is used 
to understand if differences between untreated groups, groups treated with control-ODNs 
and ODN-treated groups are statistically significant.
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 4. RESULTS 
 
4.1.   In vitro Stimulatory Potential of Dendrimeric CpG-ODNs in Mouse 
Splenocytes  
The structure of DNA backbone is an important factor in the activation of 
immune system by CpG-DNA. Most in vitro and in vivo studies utilize ODNs with 
phosphorothioate (PS) backbone due to their increased stability against nucleases and 
higher uptake rate. Yet, long-lasting effects such as lymphadenopathy, sustained local 
IFNγ and IL-12 production have been observed in PS-modified ODNs. Also, the PS 
modification brings another level of complexity and increases the cost of production for 
therapeutic purposes. Although ODNs with phosphodiester (PO) backbone have been 
shown to stimulate the immune system in a non-specific manner in one study (Yasuda et 
al., 2006), they can be superior in certain cases (Dalpke et al., 2002). 
To understand the influence of different backbones, murine splenocytes are 
stimulated with various ODNs at 0.3 µM and 1 µM concentration for 42 hours. At the 
end of the incubation period, culture supernatants are collected and analyzed for IL6 
levels by cytokine ELISA.  
As seen in Figure 15, at 0.3 µM dose, ODN420 (70-mer) with PS backbone is by 
far the most active ODN. However, ODN420 with PO backbone performs even better 
than ODN420 with PS backbone at 1 µM concentration. In other words, there is a dose-
dependent increase in IL6 secretion level for ODN420 with PO backbone while ODN420 
with PS backbone is active at very low concentrations but its activity decreases when the 
concentration increases. The 70-mer linear control ODN, ODN1466, is a modest IL6 
inducer. Additionally, ODNs 421 and 1471, in which the CG dinucleotide is flipped by 
GC, are not active. Thus, it can be concluded that this immune activation is strictly CpG-
motif dependent and mediated by TLR9.  
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Figure 15. IL6 production by murine splenocytes in response to 0.3 µM and 1 µM 
concentrations of CpG-ODN stimulation (* p<0.001). 
  
 Mouse splenocytes contain a heterogeneous population of TLR9 responsive cells 
such as B cells, dendritic cells (DC) and monocytes/macrophages as well as T cells, 
which do not express TLR9. On the other hand, TLR9 expression is restricted to only B 
cells and plasmocytoid DCs in human blood. Since one of the goals of this thesis is to 
show the potential of an ODN that can be utilized for clinical trials, we next analyze the 
effect of ODN420 in human PBMC. 
 
4.2.  In vitro Stimulation Assays Using Human PBMC 
 
4.2.1.  Activation of Dendritic Cell markers and IL6 Secretion by Human PBMC as 
a Result of Stimulation with 1 µM NP-forming ODN Treatment 
 As a preliminary experiment, blood from 2 healthy donors is collected. PBMC is 
isolated and stimulated with various ODNs at 1 µM concentration. Supernatants are 
collected at the end of 36 hours and analyzed for IL6 secretion by cytokine ELISA 
(Figure 16). Cells are analyzed for activation of DC markers (CD83 and CD86) by FACS 
(Figure 17). 
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Figure 16. IL6 secretion by human PBMC in response to 1 µM concentration of CpG-
ODN stimulation (* p<0.002). 
 
 
Figure 16 clarifies the superiority of ODN420 with respect to its linear control 
ODN-1466. At 1 µM concentration, ODN420 with PO backbone is as active as PS 
backbone. K23 is used as a positive control and D3(CG) is used as a negative control in 
this experiment. ODN422 (90-mer) is also highly active. Again, the control ODNs with 
PO backbone, which contain GC flips instead of the CG motif, are not active in human 
PBMC. Of particular interest, 421-PS and 1471-PS, control ODNs which are not 
stimulatory in mouse splenocytes, are active in human PBMC. Similar results have been 
obtained for 2nd sample (data not shown). 
In Figure 17, percentage of double positive cells (CD83+ CD86+) is 1.20, 1.58 and 
2.02 in untreated, 420-PS and 420-PO treated cells, respectively. Percentage of CD86+ 
cells is 2.46 in untreated cells. However this percentage increases to 17.69 in 420-PS 
treated cells and to 19.41 in 420-PO treated cells. Thus, DCs are shown to be activated 
upon treatment with ODN420. Although FACS analysis has been performed for cells 
treated with control ODNs, the results of those groups will be given in detail in another 
experiment in the subsequent sections of this chapter. Similar results have been obtained 
for 2nd sample (data not shown). 
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Figure 17. Activation of DC markers as a result of 1 µM CpG-ODN stimulation. CD83+ 
CD86+ cell percentage is given on the upper right corner. CD86+ cells, which are CD83- 
are given on the lower right corner of each dot plot. 
 
4.2.2. Proliferation of Immune Cells Upon Stimulation with CpG-ODNs 
With these encouraging data from preliminary studies, the next step is to analyze 
the effect of these ODNs on proliferation of immune cells and the production of tumor 
necrosis factor-alpha (TNFα).  
CFSE (carboxyfluorescein succinimidyl ester) is a commonly used fluorescent 
dye that is utilized in monitoring lymphocyte proliferation. When cells divide, CFSE 
label is distributed equally between the daughter cells. As a result, halving of cellular 
fluorescence intensity points to successive generations in proliferating cells. When 
another marker specific for a certain cell population such as T cells or NK cells is used, 
the proliferation rate of the specific cell type can be monitored. In this study, PBMC is 
isolated and cells are labeled with CFSE. Then, they are incubated with various ODNs at 
1 µM concentration for 72 hours. 10 µg/ml PHA is used as a positive control for the 
proliferation of immune cells. At the end of the incubation period, cells are stained with 
CD19. CD19 marker is expressed in all stages of B cell development until their 
maturation to plasma cells. The percentage of CD19+ cells with reduced CFSE 
fluorescence is analyzed in B cells with FACS (Figure 18). According to these results 
ODN420 with PO backbone is as effective as ODN420 with PS backbone in induction of 
B cell proliferation. These ODNs are almost as potent as PHA. However control ODNs 
with PS backbone also induces B cell proliferation in correlation with the IL6 secretion 
level in previous cytokine ELISA on human PBMC (Figure 16). It can be suggested that 
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 the optimal concentration of ODNs with PS backbone is much lower than 1 µM and the 
positive results obtained for control ODNs can be avoided when ODNs with PS backbone 
are used at lower concentrations. Among various ODNs with PO backbone, ODN420 is 
the most effective agent in induction of immune cell proliferation. 
 
 
Figure 18. Proliferating B cell percentage determined by CFSE assay and CD19 staining 
after stimulation with various ODNs at 1 µM concentration for 72 hours. * indicates a p-
value < 0.007 and ** indicates a p-value < 0.05. 
 
4.2.3.  TNFα Production by pDC After Stimulation with CpG-ODNs 
In a similar experiment setup, intracellular cytokine staining is performed and 
TNFα production levels are compared in response to different ODNs. TNFα is a crucial 
cytokine involved in systemic inflammation and is a member of a group of cytokines that 
stimulate the acute phase reaction with IL6. For intracellular TNFα staining, cells are 
incubated with 1 µM of various ODNs. Brefeldin A is immediately added to tubes to 
prevent the secretion of TNFα from cells and incubation period is 4.5 hours. At the end 
of the incubation period, cells are fixed and stained with BDCA2, CD123 and TNFα 
antibodies in permeabilization medium. CD123 is expressed in pDC and basophils while 
BDCA2 is a pDC marker. Thus, BDCA2+ CD123+ cells represent pDC and TNFα levels 
are compared in BDCA2+ CD123+ cells (Figures 19 and 20). In Figure 19, the average 
TNFα+ cell percentage among BDCA2+ CD123+ cell pDC is 1.41, 25.13, 9.24, 3.56 and 
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 5.00 in untreated cells, cells treated with ODN420-PS, ODN420-PO, ODN1466-PS and 
ODN1466-PO, respectively. These data suggest that ODN420 induces TNFα production 
by pDC much more effectively than the linear 70-mer control ODN1466. ODN420-PS 
induces 1.5-fold higher TNFα secretion than ODN420-PO. In general, if an agent induces 
high level of DC maturation and low level of TNFα production, it is a good candidate for 
IFNα induction. IFNα is a very critical cytokine for anti-viral immunity. Thus, it can be 
suggested that ODN420 with PO backbone is a better candidate for IFNα production than 
ODN420 with PS backbone. Although intracellular cytokine staining protocol for IFNα 
has been performed, a successful read-out could not be achieved (data not shown). IFNα 
is primarily produced by pDC, which constitute less than 0.1% of total cell population in 
human blood, in very low amounts. Type I IFNs (IFNα and IFNβ) and related genes have 
been analyzed by PCR in later experiments because of these challenges.  
 
 
Figure 19. TNFα-positive cells in BDCA2+ CD123+ pDC stimulated with 1 µM CpG-
ODN in selected groups. The dot plot on the upper left corner represents the gate used in 
this analysis. Percentage of triple-positive cells among BDCA2+ CD123+ pDC is given 
on the upper right corner of each dot plot. 
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 Data regarding all control groups and ODN422 is given in Figure 20. ODNs with 
specific CpG sequences (ODN420, ODN1466 and ODN422) are more effective in 
inducing TNFa secretion by pDC compared to their control sequences (ODN421, 
ODN1471, ODN423, respectively) according to these data. ODN421-PS is the only 
active ODN with PS backbone in TNFα production, which is consistent with previous 
ELISA and FACS data regarding human PBMC. Again, the reason why ODN421 is not 
active in mice but active in human is unknown at this point and should be analyzed later. 
 
 
Figure 20. TNFα-positive cells in BDCA2+ CD123+ pDC stimulated with 1 µM CpG-
ODN in all groups. (*p<0.05) 
 
4.2.4.  Dose-dependent Response of Human PBMC to NP-forming ODN Treatment 
 All previous data on human PBMC have been generated by treating the cells with 
1 µM ODN concentration to differentiate the effect of ODNs at equimolar concentration. 
Next, it is of particular interest to identify the optimal dose of NP-forming ODN 
treatment in human PBMC for understanding the behavior of each ODN and for reducing 
the amount of human cells required in subsequent gene expression studies. Human blood 
is collected from two healthy donors, PBMC is isolated and stimulated with various 
ODNs at 3 different concentrations; 0.1 µM, 0.3 µM and 1 µM. Incubation period is 24 
hours. Supernatants are collected and analyzed for IL6 and IFNg secretion by cytokine 
ELISA (Figures 21 and 22). Cells are collected and analyzed for activation of DC 
markers (CD83 and CD86) by FACS (Figures 23 and 24). 
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Figure 21. IL6 secretion by human PBMC in response to 0.1, 0.3 and 1 µM 
concentrations of CpG-ODN stimulation.  * indicates a p-value < 0.01 and ** indicates a 
p-value < 0.05.  
 
 
Figure 22. IFNγ secretion by human PBMC in response to different concentrations of 
CpG-ODN stimulation.  * indicates a p-value < 0.01 and ** indicates a p-value < 0.03.  
 
 
 IFNγ secretion could be observed only in the groups treated with ODN420 and 
ODN421. This is why data regarding other groups are not shown in Figure 22. The fact 
that ODN421 lacks CpG motifs makes the immunostimulatory activity of ODN421 
questionable. However, IFNγ secretion levels correlate with the IL6 secretion levels. Data 
in Figure 21 and Figure 22 further confirm that the activity of ODN420 with PS 
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 backbone is quite high until 0.3 µM concentration. However, at higher concentrations its 
activity is reduced. At 0.1 µM, ODN420-PS induces 10-fold higher IL6 secretion than its 
linear control ODN1466-PS. The activity of ODN420 with PO backbone is enhanced as 
its concentration increases to 1 µM. These data are further validated by DC markers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Activation of DC markers upon treatment with ODN420 at 0.1, 0.3 and 1 µM 
concentrations. CD83+ CD86+ cell percentage is given on the upper right corner. CD86+ 
cells, which are CD83- are given on the lower right corner of each dot plot. 
58 
 
 According to Figure 23, CD86+ cell percentage is 0.54 in untreated cells. Upon 
treatment with ODN420-PS, it increases to 2.16, 4.21 and 1.83 at 0.1 µM, 0.3 µM and 1 
µM concentrations, respectively. The CD86+ cells are 1.34%, 1.54% and 3.96% of the 
total live cell population in cells treated with ODN420-PO at 0.1 µM, 0.3 µM and 1 µM 
concentrations, respectively. These data again show that the optimal dose of ODN420 
with PS backbone is around 0.3 µM while ODN420-PO activity is enhanced at higher 
concentrations. Data regarding all groups is given in Figure 24.  
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Figure 24. Dose-dependent activation of DC markers upon ODN treatment. 
 
 Similar results have been obtained for 2nd sample (data not shown). Next, we 
wanted to analyze if ODN420-PO activity would increase when it is used at 3 µM 
concentration. So, a similar assay has been performed and four different concentrations 
have been performed for human PBMC from two healthy donors (Figure 25). This time 
cells have been stimulated with 0.1, 0.3, 1 and 3 µM of various ODNs. Supernatants are 
collected and analyzed for IL6 secretion. According to these results, ODN420-PS activity 
is even lower at 3 µM than its activity at 1 µM concentration. Although the difference is 
not very significant, ODN420-PO activity increases when the concentration is increased 
from 1 µM to 3 µM. Therefore, the optimal dose for ODNs with PS backbone has been 
determined as 0.3 µM while the optimal dose of ODNs with PO backbone has been 
determined as 3 µM. These concentrations are used for the subsequent gene expression 
studies.  
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Figure 25. IL6 secretion by human PBMC in response to 0.1, 0.3, 1 and 3 µM 
concentrations of CpG-ODN stimulation. * indicates a p-value < 0.03. 
 
4.2.5.  Gene Expression Studies with Human PBMC After Stimulation with NP-
forming ODNs at Optimal Doses 
 To determine the changes in endosomal TLRs and interferon-related genes upon 
stimulation with NP-forming ODNs, we have stimuled PBMC from two healthy donors 
with various ODNs for 4 hours. ODNs with PS backbone are used at 0.3 µM 
concentration and ODNs with PO backbone are used at 3 µM concentration since these 
concentrations have been previously identified as the optimal doses. Then, RNA is 
isolated and reverse transcriptase PCR is performed for gapdh, ifna, ifnb, ifng, mxa-1, 
mxa-2, tnfa, tlr3, tlr7 and tlr9 genes (Figure 26). Here, gapdh is a housekeeping gene and 
used as an internal control to show that cDNA levels of samples are in equal amounts. 
Mxa-1 and mxa-2 are critical interferon-inducible genes that function in anti-viral 
immunity. PCR products are run on agarose gel and the band intensities of stimulated 
groups are compared with untreated (naïve) group. The band intensity of naïve group is 
considered as “1” and band intensities of other groups are calculated according to this 
value. Comparison of band intensities for first sample is given in Figure 27. Similar 
results are obtained for second sample (please see Appendix). Band intensity values for 
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 genes that are not expressed at basal level cannot be compared according to this method 
and the results of treatment groups are compared among each other. 
 
Figure 26. The agarose gel picture of the RT-PCR products of tnfα, ifn-related genes and 
endosomal tlr genes. PBMCs from two donors are stimulated with NP-forming ODNs at 
optimum doses for 4 hours.  
 
 Ifnα, mxa-2, tnfα and tlr3 are not expressed at all in untreated groups (Figure 26). 
However, the expression of these genes is highly induced upon treatment with ODN420-
PS and ODN420-PO. In both samples, there is a high level of induction of ifnα. The level 
of induction with control ODNs is much lower compared to ODN420-PS and ODN420-
PO groups. In the comparison between PS and PO backbones, 420-PO induces higher 
levels of ifnα, mxa-2 and tlr3 in the first sample compared to ODN420-PS. In the second 
sample, mxa-2, tnfα and tlr3 bands cannot be visualized in the ODN420-PS group 
emphasizing the efficacy of ODN420 with natural phosphodiester (PO) backbone. Also, 
ifnb, ifng and tlr7 expression levels in ODN420-PS group are comparable with untreated 
group and expression of these genes increases 2-4 fold in ODN420-PO group in the 
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 second sample (please see Appendix B).  It can be argued that the superiority of 
ODN420-PO with respect to ODN420-PS can be caused by the concentrations used in the 
treatment. However, these concentrations have been determined as the optimal doses and 
it has been repeatedly shown that ODN420-PS activity decreases at concentrations higher 
than 0.3 µM. Thus, it can be suggested that the differences between mRNA levels 
between these two groups would become even higher if ODN420-PS were used at 3 µM, 
the concentration at which ODN420-PO has been used. 
 In the first sample, ifnβ expression significantly increases to almost 9-fold and 7-
fold upon stimulation with ODN420-PS and ODN420-PO, respectively (Figure 27A). 
Ifnγ expression is 2-fold higher and 3-fold higher in ODN420-PS and ODN420-PO 
groups respectively than basal expression level in untreated group (Figure 27B). 
Although control ODNs induce the expression of these genes up to a point, the fold 
induction in mxa-1 gene underlines the specificity of stimulation with ODN420. This 
critical interferon-inducible gene is only induced in ODN420 groups (Figure 27C). 
Again, ODN420-PO is more effective in mxa-1 induction than ODN420-PS. The changes 
in the expression level of endosomal tlr genes are very important in this study. In addition 
to the upregulation of tlr3 gene discussed above, tlr7 is expressed at 3.5-fold higher level 
in ODN420-PS treated group and 5-fold higher in ODN420-PO group (Figure 27D). 
None of the control ODNs causes an increase in the expression level of tlr7. The down-
regulation of tlr9 gene, whose product is considered to play the central role in the effect 
of CpG-ODNs, is not surprising (Figure 27E). It has been well-established that there is a 
control mechanism in the cell. When TLR9 signaling pathway is activated, its expression 
level is reduced for 8 hours to check that the danger signal really exists. If the signal 
persists after this time point, its expression is up-regulated. In this experiment, incubation 
period is 4 hours. According to these data, tlr9 expression is 90% and 60% reduced in 
ODN420-PS and ODN420-PO treated groups, respectively. Among control ODNs, 
down-regulation of tlr9 is observed only in ODN421-PS, which is again consistent with 
previous data regarding ODN421-PS activity in human cells. Therefore, the down-
regulation of tlr9 gene implies that TLR9 signaling pathway is active in groups treated 
with ODN420. Also, these data suggest that ODN420-PS is as at least as active as 
ODN420-PO and possibly even more when it is used at its optimal concentration, 3 µM. 
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Figure 27. Fold induction graphs of various interferon related genes and endosomal tlr 
genes at mRNA level for the first sample. The expression profiles of ifnb (A), ifng (B), 
mxa-1 (C), tlr7 (D) and tlr9 (E) in untreated and treated groups are compared by band 
intensities in the gel pictures in Figure 26.    
 
4.3.  In vivo Studies Utilizing Nanoparticle Forming Immunostimulatory and 
Immunosuppressive ODNs 
 
4.3.1.  In vivo Stimulatory Potential of Nanoparticle Forming ODNs 
 So far, in vitro data suggested that dendrimeric novel CpG-ODNs pose a higher 
immunostimulatory potential than the linear control ODNs and this effect is specific since 
control ODNs with GC flip sequences are not stimulatory except for ODN421-PS in 
human cells. After the promising in vitro studies, next step is naturally to test the effect of 
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 these ODNs upon injection into C57BL/6 mice. To test the in vivo effect of dendrimeric 
CpG-ODNs, they are injected intraperitoneally to mice along with conventional A-type 
ODN D35. The injected dose is 20 µg for ODNs with PS backbone and 60 for ODNs 
with PO backbone and D35. Five hours after in vivo i.p. injection, animals are 
euthanized. Spleens are removed, single cell splenocytes are prepared, RNA is isolated 
and the expression profiles of various cytokines, chemokines and tlr genes are compared 
by RT-PCR. PCR products are run on agarose gel (Figure 28) and the band intensities of 
stimulated groups are compared with untreated (naive) group (Figure 29).  
 
 
Figure 28. The agarose gel picture of the RT-PCR products of ip10, il15, ifnγ and 
endosomal tlr genes in splenocytes of mice injected with 20 µg of ODN with PS 
backbone or 60 µg of ODN with PO backbone. 
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Figure 29. Relative band intensities of various critical genes. The expression profiles of 
ip10 (A), il15 (B), ifnγ (C), tlr3 (D), tlr7 (E) and tlr9 (F) in untreated and treated groups 
are compared by band intensities in the gel pictures in Figure 28. 
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  This study reveals that dendrimeric ODNs are also active in in vivo conditions.  
The fold-induction levels are smaller with respect to in vitro studies. Yet, this is quite 
expectable because of the distribution of the agent in the organism. With respect to 
untreated group, ODN420-PS and ODN420-PO cause a 40% increase in ip10 expression 
in mouse splenocytes (Figure 29A). IP10 is a chemokine that has a critical role in 
recruitment of immune cells to sites of inflammation and its expression is inducible by 
IFNs (both type I and II). The increase of il15 expression is around 20% (Figure 29B) 
and that of ifnγ expression is around 30% (Figure 29C) in ODN420 treated groups with 
respect to untreated group. The increase in the expression of these critical genes suggests 
that the immune system is activated upon treatment with dendrimeric ODNs. ODN1466, 
the linear control of ODN420, is also quite active but it is relatively less stimulatory than 
ODN420. Meanwhile, ODN1471, the control of ODN1466 with the GC flip dinucleotide 
sequence, exhibits no stimulatory potential and the genes are expressed at a level similar 
to untreated group. The expression levels of tlr3 and tlr7 are enhanced and that of tlr9 is 
reduced upon treatment with ODN420 (Figures 29D, 29E and 29F). In all cases except 
for reduction of tlr9 expression, ODN420-PO is around 10%-40% more active in in vivo 
conditions. These results suggest that ODN420 with the natural phosphodiester backbone 
is at least as potent as its counterpart with the modified phosphorothioate backbone in 
vivo when it is used at its optimal concentration.  
 
4.3.2.  Immunization of C57BL/6 Mice with Dendrimeric ODNs and OVA in 
Combination With or Without Nanoparticle Forming Suppressive ODN 
Having established the in vivo immunostimulatory activity of ODN420, we 
wanted to investigate whether we could use this ODN as a vaccine adjuvant. In spite of 
the high potential of ODN420 with PO backbone, we decided to use ODN420-PS in this 
study because of its higher resistance against nucleases. Additionally, we wanted to find 
out if the immunosuppressive NP-forming ODN, ODNA151, would inhibit this Th1-
mediated response in the immunization protocol by increasing Th2 activity. The protocol 
is discussed in detail in the Materials and Methods section. Briefly, three adult male 
C57/BL6 mice per group are injected intraperitoneally with 15 µg of ODN-D35, ODN-
D35 or ODN-420 and 7.5 µg of OVA in combination with or without 15 µg A151. 
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 Fourteen days later, boosting injection is performed i.p. with the same ODN and OVA 
combinations. Animals are bled one day before each injection and on the twenty-seventh 
day. Animals are sacrificed on day twenty-eight and their spleens are removed. 
Background, primary and secondary sera are analyzed for the level of specific IgG 
subtypes by IgG anti-OVA ELISA (Table 11 and Table 12). Single cell splenocytes are 
studied for the expression of certain cytokines at mRNA level (Figure 30). Anti-OVA 
IgG ELISA for sera from background bleeding has revealed that all groups are positive at 
1 / 7±4 titer (data not shown). Thus, all changes in IgG levels are caused by the specific 
activity of ODNs.  
 
Table 11. IgG anti-OVA ELISA for total IgG, IgG1, IgG2a and IgG2b subtypes in sera 
from primary bleeding.  
 
 
TITER 1/N AT WHICH SERA FROM PRIMARY BLEEDING 
IS POSITIVE 
Treatment group Total IgG IgG1 IgG2a IgG2b 
Untreated 7 ± 4  7 ± 4  7 ± 4  7 ± 4 
A151+OVA 7 ± 4  7 ± 4  7 ± 4  7 ± 4 
D35+OVA 28 ± 14  7 + 14  14 ± 2  7 ± 2 
D35+A151+OVA 7 ± 4  7 ± 4  7 ± 2  7 ± 2 
420-PS+OVA 112 ± 20  7 ± 4  7 ± 2  7 ± 2 
420-PS+A151+OVA 7 ± 4  7 ± 4  7 ± 2  7 ± 2 
First number represents the average of sera titer at which IgG can be detected from three mice 
and the second number represents the standard deviation. 
 
Table 11 reveals that primary bleeding sera from D35-treated group is positive for 
IgG at a titer of 1/28. On the other hand, ODN420-treated group is positive for total IgG 
at a titer of 1/112 even before boosting injection, which is lower than that of D35. 
Meanwhile, NP-forming immunosuppressive ODN, ODNA151, in general reduces the 
total IgG, IgG2a and IgG2b titers when it is used in combination with stimulatory ODNs 
that are used as adjuvants. ODN420 in combination with A151 treated group is positive 
for total IgG at a titer of 1/7.  
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 Table 12. IgG anti-OVA ELISA for IgG, IgG1, IgG2a, IgG2b subtypes in sera from 
secondary bleeding.  
 
 
TITER 1/N AT WHICH SERA FROM SECONDARY 
BLEEDING IS POSITIVE 
Treatment group Total IgG IgG1 IgG2a IgG2b 
Untreated 7 ± 4  7 ± 4  7 ± 4  7 ± 4 
A151+OVA 7 ± 4  7 ± 4  7 ± 4  7 ± 4 
D35+OVA 1792 ± 500  1300 ± 450  112 ± 12  112 ± 12 
D35+A151+OVA 28 ± 14  28 ± 12  7 ± 2  7 ± 2 
420-PS+OVA 4000 ± 800  1500 ± 300  448 ± 50  28 ± 4 
420-PS+A151+OVA 792 ± 480  500 ± 25  7 ± 4  7 ± 4 
First number represents the average of sera titer at which IgG can be detected from three mice 
and the second number represents the standard deviation. 
  
 Data from secondary bleeding (Table 12) is even more informative because high 
IgG values are expected to be seen after the boosting injection in immunization protocols. 
Untreated and A151-treated groups are not positive for any IgG at titers lower than 1/7, 
as expected. In the comparison between the efficacy of D35 and ODN420 as vaccine 
adjuvants, D35-treated group is positive for total IgG, IgG1, IgG2a and IgG2b at titers of 
1/1792, 1/1300, 1/112 and 1/112, respectively. However, ODN420-treated group is 
positive for this IgGs at titers of 1/4000, 1/1500, 1/448 and 1/28, respectively. Thus, 
ODN420 induces higher levels of IgGs than ODN-D35 except for only IgG2b. The 1/448 
titer at which IgG2a is positive suggests that ODN420 induces a strong Th1 response. In 
correlation with the data from primary bleeding, A151-treatment down-regulates the Th1 
response in the immunization protocol. In ODN420 in combination with A151 treated 
group, positive titers are 1/792, 1/500, 1/7 and 1/7 for total IgG, IgG1, IgG2a and IgG2b, 
respectively. Thus, the efficacy of ODN420 is lowered as an adjuvant. In general, the 
IgG2a/IgG1 ratio implies the strength of Th1 response. The higher the IgG2a and the 
lower the IgG1, the more effective the Th1 response. Significantly, the 1/500 titer and the 
1/7 titer at which ODN420 and A151-treated group is positive for IgG1 and IgG2a 
indicate that the Th1 response is strongly suppressed. We cannot reach to the conclusion 
that this is achieved by enhancing Th2 response with these data. Further studies such as 
IL4 ELISA are required to show that ODN-A151 increases Th2 response. 
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  These data imply that ODN420 can be successfully used as a vaccine adjuvant 
and is a strong inducer of Th1 response. Meanwhile, ODN-A151 lowers the Th1 response 
that is caused by various ODN adjuvants and OVA. ODN-A151 treatment has no effect 
by itself. Yet, if a strong Th1 response is generated, ODN-A151 fine-tunes and reduces 
the Th1 response possibly by causing a shift to Th2 response, according to these data. 
These results are also validated by RT-PCR of critical genes involved in immune system. 
Both up-regulation of critical genes involved in immune system upon dendrimeric ODN-
treatment and the fine-tuning, which results in down-regulation of these genes, upon 
ODN-A151 treatment are further confirmed by RT-PCR results (Figure 30). Band 
intensity analysis reveals that ODN420 induces 50% higher ifnγ expression with respect 
to untreated group (data not shown). D35 and ODN-420 cause a general increase in 
transcription of cd40, il15 and ifnγ. The up-regulation effect is hindered when these 
stimulatory ODNs are used in combination with ODN-A151. 
 
Figure 30. The agarose gel picture of the RT-PCR products of ip10, il15, ifnγ and 
endosomal tlr genes in splenocytes of mice immunized with two doses of 15 µg ODN and 
7.5 µg OVA. 
 
 
 
 
 
4.3.3. Use of Nanoparticle Forming ODNs as Anti-Cancer Agents  
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  CpG-ODNs are known to induce anti-tumor immunity by a variety of 
mechanisms including induction of CD8+ cytotoxic T cells, up-regulation of MHC 
molecules by tumor cells as well as antigen-presenting cells and interfering with the 
immunosuppressive microenvironment generated by tumors. Approximately 30% of 
cancer cases are caused by an inflammatory background and details of the relationship 
between cancer and inflammation are being recently discovered. For example, NF-kB is a 
central transcription factor in inflammatory response. Yet, it also causes production of 
angiogenic factors and growth signals that can promote malignant progression. With 
these data in literature, we wanted to test the effect of ODN-420 and ODNA151 in tumor 
xenografts. Details of this experiment are given in the Materials and Methods section. 
Briefly, Huh7 cells, a human hepatocellular carcinoma cell line, are xenografted into T-
cell deficient nude mice. Since tumor formation is heterogeneous and some nude mice 
develop tumors later than 3 weeks, the day on which a palpable tumor forms is 
considered as day 0. Three doses of 100 µg of ODN-420 or ODN-A151 are injected 
intratumorally with one day-on and one day-off treatment starting from day 3 post-
palpable tumor formation. Tumor dimensions are recorded daily as width, height and 
length by a caliper and calculated as mm3 (Figure 31A and Figure 31B). Pictures of 
tumor xenografts in untreated and ODN420-treated mice are given in Figure 32. 
A) 
 
 
B) 
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Figure 31. The effect of nanoparticle forming ODNs as anti-cancer agents. Tumor 
volumes of untreated mice and mice treated with ODN-420 are given in (A). Tumor 
volumes of untreated mice and mice treated with ODN-A151 are given in (B). 
  
 
Figure 32. Tumor xenografts in untreated and ODN420-treated mice at days 35 and 42 
post palpable tumor formation, respectively. 
 
Although it might seem confusing to study both immunostimulatory and 
immunosuppressive ODNs as anti-cancer agents, cancer is a very complex disease. While 
an anti-tumor immunity is critical for the organism’s response against cancer, an 
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 inflammatory micro-environment can support the growth of tumor. At day thirty-five 
tumor volume is 5586 mm3 in untreated mice. At the same day, tumor volumes are 900 
mm3 and 72 mm3 in mice treated with ODN-420 (Figure 32). According to these data, 
ODN-420 treatment can cause partial remission of the tumor. This effect is observed in 
one mouse treated with ODN-420. The growth of tumor is delayed in the other animal in 
the same group. In the comparison between ODN-A151 treated tumor xenografts and 
untreated xenograft, ODN-A151 cannot induce remission of the tumor but only delay the 
tumor growth (~d=30). Therefore, ODN-420 is a more promising candidate as an anti-
cancer agent than ODN-A151. Certainly, sample size should be increased in the future 
experiments for statistical significance of these data. 
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 5. DISCUSSION  
CpG ODNs are of great importance for the regulation of the immune system. 
While K-type ODNs induce higher levels of IL12 and TNFα, D-type ODNs stimulate 
higher levels of anti-viral type I IFNs and induce maturation of monocytes into DCs.  
While each class of CpG ODN (D-type, K-type, C-type), results in different activities, 
these differences are also brought forth by several factors. These factors are the number 
of CpG motifs on one strand, backbone chemistry (PS vs. PO), flanking sequences (Pu-
Pu-C-G-Py-Py or Pu-Py-C-G-Pu-Py), presence of poly-G runs at terminal end and the 
physical structure of the ODN (linear single-strands vs. multimeric structures that form 
nanoparticles). One challenge in the identification of optimal CpG sequences for human 
studies is that many ODNs that are active in mice, do not exhibit similar 
immunostimulatory potentials in human cells. 
 ODNs that are able to form multimeric structures and are of nanoparticulate 
nature are superior in their immunostimulatory potentials than those that remain as 
single-stranded linear structures for several reasons. First, they are retained in early 
endosomes for a longer period and able to promote type I IFN production. Second, they 
pose higher activity under physiological conditions. Because of premature serum protein 
binding and exonuclease activity, most of the administered ODNs are 
degraded/eliminated before they reach the relevant target immune cells. Finally, they are 
superior to their linear counterparts in terms of effective internalization. A scavenger 
receptor, CXCL16, is used as a co-receptor in the uptake of ODNs with nanoparticulate 
nature (Gursel et al., 2006). This scavenger receptor does not promote the uptake of 
ODNs that remain as linear structures in the body.  
During various attempts to manipulate the physical structure of ODNs and 
increase its resistance to nucleases, CpG ODN has been previously loaded into 
nanoparticulate phospholipid carriers such as liposomes. ODNs loaded into sterically 
stabilized cationic liposomes are more effectively internalized by immune cells and 
exhibit immunostimulatory activity at low concentrations (Gursel et al., 2001). 
Additionally, linear ODNs complexed with particulate carriers such as DOTAP 
liposomes or polymyxin have been also shown to exhibit IFNα production (Guiducci et 
al., 2006; Honda et al., 2005a). This shows that the primary determinant of immune 
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 activation is not ODN type or the sequence but the endosomal localization of ODNs. 
Another group has taken a different approach to construct ODNs with multimeric 
structures and has shown that addition of poly-G tails to ODNs with PO backbone can 
enable multimerization and thus sequence independent IFNα production (Haas et al., 
2009). 
We have designed a novel dendrimeric ODN, ODN-420, which spontaneously 
folds into a multimeric structure and exhibits high immunostimulatory potential 
(Mammadov, M.Sc. thesis). It contains 7 CG motifs and has the potency to exhibit more 
resistance against nucleases because of its nanoparticulate nature without the use of an 
additional carrier system (Karatepe, Mammadov and Gursel, unpublished data). To date, 
there is no reported dendrimeric ODN in the literature. Previous studies have focused on 
the activity of this ODN with the more nuclease resistant PS backbone on mouse 
splenocytes. However, this modification brings another level of complexity and increases 
the cost of production in large scale synthesis. We have analyzed whether ODN420 with 
the natural PO backbone would be as active as ODN420 with the PS backbone and 
whether ODN420 would be a potent type I IFN inducer. For a preliminary in vitro study, 
we have incubated mouse splenocytes with different concentrations of dendrimeric ODNs 
and the control ODNs. As shown in Figure 15, at low dose (0.3 µM), ODN420-PS 
exhibits a much higher activity in comparison to ODN420-PO, as expected. However, 
this difference is not observed at 1 µM concentration, where ODN420-PO is even more 
immunostimulatory than ODN420-PS. In control ODNs (ODN421 and ODN1471), 
where the CpG motif is fliped by a GpC motif, there was no activity. This shows that the 
immune activation is CpG-motif dependent and mediated by TLR9, rather than the 
sequence-independent effects of these long ODNs. Additionally, the linear 70-mer 
ODN1466 is a less potent inducer of IL6 than the dendrimeric ODNs. This clarifies that 
the level of immune activation is dependent on the multimeric structure formed by 
dendrimeric ODNs. 
After establishing that ODN420-PO is as active as ODN420-PS at 1 µM in mice 
splenocytes, we next analyzed the activity of these ODNs on human peripheral blood 
mononuclear cells (PBMC) with various assays. As previously mentioned, sequences 
with high immunostimulatory potential in mouse cells, are rarely active at comparable 
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 levels in human cells because of the differences in the optimal sequences in human and 
mice cells. For this assay, human PBMC have been incubated with 1 µM of various 
ODNs. IL6 secretion levels have been compared by ELISA and DC activation marker 
levels have been assessed by flow cytometry. In Figure 16, it is observed that ODN420 
with PO backbone is as active as PS backbone at 1 µM. These results correlate with data 
from mice splenocytes. Again, the control ODNs with PO backbone, which contain 
flipped motifs of GC instead of the CG motif, are not active in human PBMC. Of 
particular interest, 421-PS and 1471-PS control ODNs which are not stimulatory in 
mouse splenocytes, are found to be active in human PBMC albeit, there is a donor to 
donor variation. Analysis of relevant DC activation markers, which gives information on 
the maturation/activation of antigen presenting cells, has been performed in Figure 17. 
These results have revealed that ODN420 both with the PS backbone and PO backbone 
trigger the activation of antigen presenting cells.  
In another experiment, the effect of dendrimeric ODNs on proliferation of B cells 
has been analyzed. Figure 18 shows that ODN420-PO is as effective as ODN420 with PS 
backbone in the induction of B cell proliferation at 1 µM. It is important to note that, 
1µM ODNs were used in this experiment, PS backbone ODNs were known to induce 
sequence non-specific B-cell proliferation (Liang et al., 1996). To distinguish CpG 
specific cell proliferation a dose titration experiment between control and CpG ODN is 
needed. In our case PS ODNs (independent of CpG motifs) are as potent as the positive 
control PHA. Of note, ODN420PO gave CpG specific proliferation higher than the linear 
CpG counterpart at 1 µM. In a similar experimental setup, intracellular cytokine staining 
is performed and TNFα production levels by pDC are compared in response to different 
ODNs.  According to Figure 19, ODN420-PS and ODN420-PO induce high levels of 
TNFα production in comparison to their linear controls, ODN1466-PS and ODN1466-
PO. Figure 20 shows that other control ODNs are not active and do not induce TNFα 
production except for ODN421-PS. 
Next, we have performed an assay to understand the optimal doses in NP-forming 
ODN treatment in human PBMC in order to understand the behavior of each ODN. 
Figures 21 and 22 show that IL6 and IFNγ secretion levels increase in ODN420-PO 
treatment as the concentration increases from 0.1 µM to 1 µM while the secretion levels 
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 are reduced in ODN420-PS treatment at concentrations higher than 0.3 µM. DC 
activation markers have correlated well with these results (Figures 23 and 24). Another 
assay has been performed to study the 3 µM concentration. As can been seen in Figure 
25, ODN420-PO activity is further improved at 3 µM. Thus, these results have shown 
that ODNs with PS backbone are optimally active at 0.3 µM while ODNs with PO 
backbone are optimally active at 3 µM.  
It has been previously established that immune cells differentially respond to 
different types of CpG ODNs. D-type ODNs preferentially stimulate IFNγ production by 
NK cells, whereas the K-type ODNs stimulate cell proliferation and the production of IL6 
and IgM by monocytes and B cells (Verthelyi et al., 2001). Another study has further 
characterized the differential response to different CpG ODNs. Krug et. al. has identified 
certain CpG ODNs, which are referred as D-type ODNs,  induce high levels of IFNα/β in 
human pDC in contrast to K-type ODNs, which strongly activate human B cells and 
blood DCs (Krug et al., 2001). We wanted to identify whether ODN420 would also 
induce type I IFNs (IFNα/β). As mentioned earlier, this cytokine is critical against viral 
infections. Moreover, throughout this work one of the most important goals is to 
demonstrate the breadth of activation of this novel NP-ODN both in mice and man. So, 
human PBMC have been treated with various ODNs at optimal doses and various 
interferon-related genes have been analyzed. Data from Figures 26 and 27 suggest that 
the expression levels of ifnα, ifnβ, ifnγ and other interferon-relate genes such as mxa-1 
and mxa-2 are greatly induced upon treatment with ODN420. Type I IFN induction 
ability of ODN420-PO is higher than that of ODN420-PS. While it can be argued that 
this difference is caused by the fact that the concentration of ODN420-PO is 3 µM and 
ODN420-PS is 0.3 µM, we would suggest that the differences would become even higher 
if ODN420-PS were used at 3 µM, the concentration at which ODN420-PO has been 
used. Although it was not possible to study the secreted protein by ELISA, the gene 
transcript findings of mxa-1 and mxa-2 in addition to ifnα, ifnβ, strongly suggest that our 
sequences are potentially type I IFN producers. The literature findings suggested that 
MxA proteins were IFNα/β induced GTPases that inhibits the multiplication of several 
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 RNA viruses by interacting with the viral nucleocapsid (Peltekian et al., 2005; 
Schwemmle et al., 1995).  
Up to this point, various immunostimulatory activities of ODN420 have been 
analyzed by in vitro studies. Induction of high levels of IL6, TNFα, B cell proliferation 
and activation of pDC maturation markers are superior properties of K-type ODNs. 
Meanwhile, induction of type I IFNs (IFNα/β), that are critical in anti-viral immunity, is 
a property of D-type ODNs. Therefore, our dendrimeric ODN, ‘420’ is a novel DNA-
based agent and possesses the superior characteristics of both K-type and D-type ODNs. 
Another interesting point is the optimal concentrations of ODN420-PS and ODN420-PO. 
K-type ODNs are active at an optimal dose of 1 µM and maximal activity of D-type 
ODNs is reached at 3 µM. Interestingly, ODN420-PS is active at 0.3 µM and ODN420-
PO is most active at 3 µM. Therefore, at this point, it would not be possible to classify 
this novel ODN as D-type or K-type. It can be suggested that this novel ODN combines 
useful properties of both types. This is a novel class of CpG ODNs.  Since it is devoid of 
poly-G runs and conforms to a nanoparticle structure, we can regard this ODN as a new 
class. It also possesses more than one CpG motifs attached to a single sequence, and it is 
equally active in mice and humans. Furthermore, the PO forms are as potent as the PS 
backbone forms.  
As previously mentioned, ODNs with PS backbone are more resistant to 
nucleases under physiological conditions. At this point, we have hypothesized that 
ODN420-PO would be stable in vivo and exhibit immunostimulatory activity at a level 
comparable with ODN420-PS due to it increased resistance conferred by the formation of 
nanoparticulate structure. We have then injected mice with various ODNs 
intraperitoneally and removed their spleens five hours after injection. Upon analysis of 
various cytokines and chemokines, it has been shown that ODN420 with the natural PO 
backbone is at least as potent as its counterpart with the modified PS backbone in vivo 
when used at its optimal concentration (Figures 28 and 29). Although a higher dose is 
used for ODN420-PO, these results still show that ODN420-PO is stable under 
physiological conditions and at least a sufficient amount of ODNs is able reach the 
targeted immune cells and activate TLR9 signaling before undergoing degradation by 
nucleases. 
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 Having established the potentials of ODN420-PO, we have decided to use 
ODN420-PS for the subsequent animal experiments. The overall response to CpG ODNs 
is Th1-mediated. Here we have assessed whether this ODN could be used as a vaccine 
adjuvant in following mouse experiments. ODN420 and OVA-treated group is positive 
for total IgG at a titer of 1/112 even before booster injection (Table 11). This effect is 
more pronounced after booster injection. D35-treated group is positive for total IgG, 
IgG1, IgG2a and IgG2b at titers of 1/28, 1/1300, 1/112 and 1/112, respectively. However, 
ODN420-treated group is positive for these IgGs at titers of 1/4000, 1/1500, 1/448 and 
1/28, respectively (Table 12). Thus, ODN420 induces higher levels of IgGs than ODN-
D35 except for IgG2b. These results have shown that ODN420 induces a Th1-mediated 
immunity and can be effectively used as a vaccine adjuvant. In this experiment, the 
potential of another class of NP-forming ODN with immunosuppressive activity has also 
been analyzed. In the case of tissue injury, necrosis may occur and host DNA, which is 
rich in telomeric TTAGGG repeats, may be released into the surrounding tissue. It has 
been previously shown that ODNs with these repetitive elements can suppress the 
immune system by forming G-tetrads (Dong et al., 2004; Zeuner et al., 2002). The ability 
of these ODNs to suppress the immune system is dependent on their ability to form 
nanoparticles. We have analyzed whether this immunosuppressive ODN, ODN-A151, 
would interfere with the immune response generated during immunization. In secondary 
bleeding, positive titers are 1/792, 1/500, 1/7 and 1/7 for total IgG, IgG1, IgG2a and 
IgG2b, respectively, for ODN420 in combination with A151-treament group. Thus, 
treatment with ODN-A151 has decreased total IgG and IgG subtype levels generated by 
immunization with various adjuvants and OVA and reduced the Th1 response. Analysis 
of various Th1-related cytokines has confirmed these results (Figure 30). 
Finally, we next asked whether both ODN420 and ODN-A151 could be utilized 
as anti-cancer agents. We have hypothesized that both immunostimulatory and 
immunosuppressive nanoparticle-forming ODNs could be utilized against cancer due to 
the complexity of the molecular mechanisms underlying cancer. While ODN420 can 
promote anti-tumor immunity, ODN-A151 can suppress the inflammatory response, 
which may provide favorable conditions for tumor growth. Tumor xenografts are 
established in nude mice by injection of Huh7 cells. Animals are treated with 100 µg of 
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 either ODN420 or ODN-A151 starting from 3 days after the formation of a palpable 
tumor with one day-on one day-off treatment for three doses. According to Figure 31A, 
ODN-420 treatment can achieve partial remission of the tumor. This effect is observed in 
one mouse treated with ODN-420. The growth of tumor is delayed in the other animal in 
the same group. Meanwhile, ODN-A151 cannot induce remission of the tumor; it is able 
to delay its growth (Figure 31B). Therefore, ODN-420 is a more promising candidate as 
an anti-cancer agent than ODN-A151. Definitely, this experiment should be repeated and 
sample size should be increased in the following experiment for generation of more 
reliable and statistically significant data. However, this preliminary data suggests that 
ODN420 can be a promising candidate as an anti-cancer agent. The mechanism of 
ODN420 as an anti-cancer agent can be attributed to activation of NK cells and 
granulocytes in nude mice. These parameters should also be subject for further analysis. 
To sum up, we have shown that ODN420 exhibits high immunostimulatory 
potential with respect to conventional linear or multimeric ODNs. ODN420-PS exhibits 
immunomodulatory activity at concentrations such as 0.1 µM, where other ODNs are not 
active. ODN420-PO is not active at such low concentrations but it is even more potent 
than ODN420-PS at concentrations such as 1 µM. The activity of the natural 
phosphodiester (PO) backbone is very promising because PS-modification of the 
backbone structure adds another level of complexity to the system and increases the cost 
of production in large scale synthesis. While conventional ODNs with PO backbone are 
easily degraded by nucleases in vivo, we have shown that ODN420-PO is also active 
under physiological conditions possibly due to its ability to form nanoparticles. The 
immunostimulatory potential of these ODNs in human PBMC has been analyzed by 
various assays and it has become clear that this ODN exhibits superior characteristics of 
both D-type ODNs and K-type ODNs. While ODN420 induces high levels of IL6, IL12, 
TNFα, B cell proliferation and activation of pDC maturation markers, it also induces 
production of type I IFNs (IFNα/β). Finally, it has been shown that this ODN can be used 
as a Th1-promoting vaccine adjuvant as well as an anti-cancer agent. 
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 6. FUTURE STUDIES 
While animal experiments are critical for designing CpG ODNs for 
immunotherapeutic purposes, optimal sequences for mice and human share only 75% 
homology. Therefore, many sequences, which are active in mice, do not exhibit 
correlating immunostimulatory potentials in human trials. We have identified a unique 
nanoparticle-forming CpG ODN that exhibits high immunostimulatory activity in mice 
and reproduced these results in human peripheral blood cells. 
 While ODN420 treatment has up-regulated type I IFNs and various interferon-
related genes in human cells, these results should be reproduced in mice studies. 
Additionally, these data have been obtained at mRNA level and should be confirmed in 
protein level with FACS or ELISA. Additionally, tumor xenograft experiment should be 
repeated with a larger sample size and the immunization experiment should be repeated 
with disease-specific antigens instead of OVA. 
 Previous studies have identified that pre-treatment of mouse splenocytes with 
dextran sulfate, which is a ligand for scavenger receptors, completely abrogates the 
immunostimulatory activity of ODN420 (Mammadov, M.Sc. thesis). These data indicate 
that a scavenger receptor such as CXCL16, which is a co-receptor for D-type ODNs 
(Gursel et al., 2006), is responsible for the more efficient uptake mechanism of ODN420. 
To explain the underlying mechanism of NP-forming ODN uptake and efficiency, 
antibodies against individual scavenger receptors should be used in both in vitro and in 
vivo studies.  
 Also, several discrepancies have been observed in human donors in response to 
stimulation with NP-forming ODN treatment. It is well-established in the literature that 
the efficacy of CpG ODNs is highly deviant between patients. Thus, the number of 
donors in human studies should be increased to gain a better understanding on the action 
of ODN420 and to show that it is effective in large populations. 
 Another set of experiments should utilize specific cell types. For example, D-type 
ODNs are known to exhibit low stimulatory potential on B cells. We have worked on 
either human PBMC or mice splenocytes to identify the effects of ODN420. These 
samples contain heterogenous populations of cells. Similar experiments should be 
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 performed on specific cell subsets such as B cells or pDC to further characterize the 
immunomodulatory activity of ODN420 on distinct cell types. 
 Finally, shorter dendrimeric ODNs can be designed and their immunostimulatory 
potentials can be analyzed. Current literature suggests that the minimum length of a CpG-
ODN sequence is 8 bases for a single strand. However, it is possible that even shorter 
sequences may be immunostimulatory when they are used in dendrimeric ODNs. 
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 8. APPENDICES 
8.1. Appendix A 
Buffers, Solutions, Culture media 
Blocking Buffer (ELISA) 
• 500 ml 1x PBS 
• 25 grams BSA (5%) 
• 250 µl Tween20 (0,025%) 
Crystal particles of BSA should be dissolved very well, with magnetic-heating stirrer 
for 20-30 min. The buffer should be stored at -20°C. 
Loading Dye (Agarose gel)
• 0,009 grams Bromofenol blue  
• 0,009 grams Xylen cyanol  
• 2,8 ml ddH2O 
• 1,2 ml 0,5M EDTA 
• 11 ml glycerol 
After preparing, just vortex it. 
PBS (Phosphate Buffered Saline) [10x] 
• 80 grams NaCl 
• 2 grams KCl 
• 8,01 grams Na2HPO4 . 2H2O 
• 2 grams KH2PO4 
complete into 1 lt with ddH2O (pH= 6,8).  
For 1X PBS’s pH should be ≈ 7,2-7,4 and should be autoclaved prior to use. 
TAE (Tris-Acetate-EDTA) [50x] 
• 242 grams Tris (C4H11NO3) 
• 37,2 grams Tritiplex 3 (EDTA= C10H14N2Na2O2 . 2H2O) 
• 57,1 ml Glacial acetic acid 
Complete to 1 lt final volume with ddH2O. Autoclaved and diluted to 1X prior to use. 
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 PBS-BSA-Na azide 
• 500 ml 1x PBS 
• 5g BSA (1%) 
• 125mg  (0,25%) 
T-cell Buffer [ELISA] 
• 500 ml 1x PBS 
• 25 ml FBS (5%) 
• 250 µl Tween20 (0,025%) 
The buffer should be stored at -20°C. 
Wash Buffer [ELISA] 
• 500 ml 10x PBS 
• 2,5 ml Tween20   
• 4,5 lt ddH2O 
RPMI-1640 (Hyclone) 
• 2  % : 10 ml FBS (Oligo FBS = inactivated at 65°C, Regular FBS = inactivated at 
55°C ) 
• 5   % : 25 ml FBS 
• 10 % : 50 ml FBS 
• 5 ml Penicillin/Streptomycin (50 µg/ml final concentration from 10 mg/ml stock) 
• 5 ml HEPES (Biological Industries), (10 mM final concentration from 1M stock ) 
• 5 ml Na Pyruvate, (0,11 mg/ml final concentration from 100mM, 11 mg/ml stock) 
• 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x concentrate 
stock) 
• 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml stock) 
In 500 ml media 
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 8.2. Appendix B 
Fold induction graphs of various interferon related genes and endosomal tlr genes at 
mRNA level for stimulations from the second donor. The picture of agarose gel 
electrophoresis is given in Figure 26. 
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